Protocol Number: KO-TIP-007 
 
Official Title:  The AIM -HN and SEQ -HN Study: A Multi -national, Single Arm Pivotal  Study Evaluating 
the Efficacy of Tipifarnib in Patients with Head and Neck  Squamous Cell Carcinoma (HNSCC) with 
HRAS Mutations (AIM- HN) and an Observational Study to Evaluate the Impact of HRAS Mutational 
Status  on Response to First Line Systemic Therapies  for HNSCC (SEQ -HN) 
Study ID: [REMOVED]  
 
Document Date: 09 J une 2020 

Tipifarnib   
CTP KO-TIP-007          Page 1 
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL    
 
 
 
CLINICAL TRIAL PROTOCOL  
Protocol Number : KO-TIP-007 
Title: The AIM -HN and SEQ -HN Study: A 2 Cohort, Non -comparative, Pivotal Study 
Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma 
(HNSCC) with HRAS Mutations (AIM -HN) and the Impact of HRAS Mutations on Response to 
First Line Systemic Therapies for HNSCC (SEQ -HN). 
US IND Number:  127,209 
EudraCT Number:  2018 -001437 -40 
Version:  Final:   14 June 2018  
 Amendment 1:  25 July 2018  
 Amendment 2:  15 November 2018  
 Amendment 3:   9 June  2020  
 
Sponsor : Kura Oncology, Inc . 
3033 Science Park Road, Suite 220  
San Diego , CA 92 121 (USA)  
Phone: +1 858.500.880 3  
(Note: effective 12 June 2020, Kura has a new address)  
12730 High Bluff Drive, Suite 400   
San Diego, CA 92130  
Phone: +1 858.500.8803    
 
Protocol Author:    
 
CONFIDENTIAL  
This document contains proprietary and confidential information of  Kura Oncology, Inc.  Acceptance of this 
document constitutes agreement by the recipient that no previously unpublished information contained herein will 
be published or disclosed without the prior written approval of Kura Oncology, Inc.  with the exception that this 
document m ay be disclosed to study personnel under your supervision who need to know the contents for 
conducting the study and appropriate Institutional Review Boards (IRBs)/Ethics Committees (EC) under the 
condition that the personnel have agreed to keep this infor mation confidential. The foregoing shall not apply to 
disclosure required by governmental regulations or laws, however, Kura Oncology, Inc. shall be promptly notified 
of any such disclosure.   

Tipifarnib   
CTP KO-TIP-007          Page 3 
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   1 TABLE OF CONTENTS  
Section   
1 TABLE OF CONTENTS  ................................ ................................ .....3 
2 STUDY SYNOPSIS  ................................ ................................ ............. 9 
3 LIST OF ABBREVIATIONS  ................................ ............................. 26 
4 BACKGROUND  ................................ ................................ ................ 28 
4.1 Investigational Agent  ................................ ................................ .......... 28 
4.2 Study Rationale  ................................ ................................ ................... 28 
4.2.1  Head and  Neck Squamous Cell Carcinoma  ................................ ........ 28 
4.2.2  Mechanism of Action  ................................ ................................ ......... 29 
4.2.3  Clinical Development  ................................ ................................ ......... 30 
4.3 Risk/Benefits  ................................ ................................ ....................... 31 
4.4 Dose Rationa le ................................ ................................ .................... 32 
4.5 Trial Conduct  ................................ ................................ ...................... 33 
4.6 Population  ................................ ................................ ........................... 34 
5 TRIAL OBJECTIVES  ................................ ................................ ........ 35 
6 TRIAL DESIGN  ................................ ................................ ................. 36 
6.1 Study Endpoint s ................................ ................................ .................. 36 
6.1.1  Primary Endpoint  ................................ ................................ ................ 36 
6.1.2  Key Secondary Endpoints  ................................ ................................ ...36 
6.1.3  Other Secondary Endpoints  ................................ ................................ 37 
  
 
6.2 Study Design  ................................ ................................ ....................... 37 
6.2.1  AIM -HN Design  ................................ ................................ ................. 38 
6.2.2  SEQ -HN Design  ................................ ................................ ................. 40 
6.3 Randomizat ion ................................ ................................ .................... 40 
6.4 Maintenance  ................................ ................................ ........................ 40 
6.5 Trial Treatment  ................................ ................................ ................... 41 
6.5.1  Investigational Product (IP)  ................................ ................................ 41 
6.5.2  Product Characteristics  ................................ ................................ .......41 
6.5.3 Storage and Labeling  ................................ ................................ .......... 41 
6.5.4  Emergency Medical Support and Subject Card  ................................ ..42 

Tipifarnib   
CTP KO-TIP-007          Page 4 
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   6.6 Duration  ................................ ................................ .............................. 42 
6.7 Discontinuation  ................................ ................................ ................... 43 
6.7.1  Definition of End of Study  ................................ ................................ .43 
6.7.2  Premature Discontinuation of the Trial  ................................ .............. 43 
6.8 Product Accountability  ................................ ................................ .......44 
6.9 Data Identification  ................................ ................................ .............. 44 
6.9.1  Subject Identification and Privacy  ................................ ...................... 44 
6.9.2  Case Report Form Management  ................................ ......................... 45 
6.9.3  Source Data and Subject Files  ................................ ............................ 45 
7 SELECTION AND WITHDRAWAL O F SUBJECTS  ...................... 46 
7.1 Inclusion Criteria  ................................ ................................ ................ 46 
7.1.1  Inclusion Criteria: AIM -HN ................................ ............................... 46 
7.1.2  Inclusion Criteria: SEQ -HN ................................ ............................... 48 
7.2 Exclusion Criteria  ................................ ................................ ............... 49 
7.2.1  Exclusion Criteria: AIM -HN ................................ .............................. 49 
7.2.2  Exclusion Criteria: SEQ -HN ................................ .............................. 50 
7.3 Subject Withdrawal  ................................ ................................ ............ 50 
7.3.1  Remo val of Subjects from Treatment or Assessment  ......................... 50 
7.3.2  Medical Care of Subjects after End of Trial  ................................ .......51 
7.3.3  Replacement of Subjects  ................................ ................................ .....51 
8 TREATMENT OF SUBJECTS  ................................ .......................... 52 
8.1 Medication  ................................ ................................ .......................... 52 
8.1.1  Tipifarnib Administration  ................................ ................................ ...52 
  
8.1.3  Treatment of Tipifarnib Overdose  ................................ ...................... 57 
8.1.4  Prior and Concomitant Medications  ................................ ................... 57 
8.1.5  Non-permitted Treatments  ................................ ................................ ..58 
8.1.6 Dietary or Other Protocol Restrictions  ................................ ............... 59 
8.2 Monitoring of Subject Compliance  ................................ .................... 60 
9 STUDY PROCEDURES  ................................ ................................ ....60 
9.1 Pre-screening for HRAS Mutation  ................................ ..................... 60 
9.1.1  Subjects With Known HRAS Mutation  ................................ .............. 61 

Tipifarnib   
CTP KO-TIP-007          Page 5 
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   9.1.2  Subjects Without Known HRAS Mutational Status: Testing for 
HRAS mutation at a Spon sor Designated Laboratory  ........................ 62 
9.1.3  Subjects Without Known HRAS Mutational Status: Local testing 
for HRAS mutation using a Sponsor app roved test:  ........................... 62 
9.1.4  Subjects who have HNSCC without HRAS mutation  ........................ 63 
9.2 AIM -HN ................................ ................................ ............................. 63 
9.2.1  Screening Proced ures ................................ ................................ .......... 63 
9.2.2  Day 1 of Cycle 1  ................................ ................................ ................. 66 
9.2.3  Day 7 of Cycle 1  ................................ ................................ ................. 67 
9.2.4  Day 1 (± 2 days) of Cycle 2  ................................ ................................ 67 
9.2.5  Day 1 (± 2 days) of Cycle 3 and Beyond  ................................ ............ 68 
9.2.6  Tumor Response Assessment Visits  ................................ ................... 68 
9.2.7  End of Treatment Visit  ................................ ................................ .......69 
9.2.8  Follow up Visit  ................................ ................................ ................... 70 
9.2.9  Follow Up Contact  ................................ ................................ .............. 71 
9.3 SEQ -HN ................................ ................................ .............................. 71 
9.3.1  Screening Procedures  ................................ ................................ .......... 71 
9.3.2  Study Enrollment  ................................ ................................ ................ 71 
9.3.3  On Study Visit  ................................ ................................ .................... 72 
9.3.4  Follow Up Contact  ................................ ................................ .............. 73 
10 ASSESSMENT OF EFFICACY  ................................ ........................ 73 
10.1  Efficacy Parameters  ................................ ................................ ............ 73 
10.1.1  Efficacy Variables ................................ ................................ ............... 73 
10.1.2  Method and Timing  ................................ ................................ ............ 73 
10.2  Additional Variables  ................................ ................................ ........... 74 
10.2.1  Population Pharmacokinetics  ................................ .............................. 74 
10.2.2  Biomarker s ................................ ................................ .......................... 75 
11 ASSESSMENT OF SAFETY  ................................ ............................. 76 
11.1  Safety Parameters  ................................ ................................ ............... 76 
11.2  Metho d and Timing  ................................ ................................ ............ 76 
11.2.1  Monitoring of Subjects with Adverse Events  ................................ .....76 
11.2.2  Pregnancy and In Utero Drug Exposure  ................................ ............. 77 
11.2.3  Laboratory Assessments  ................................ ................................ .....77 

Tipifarnib   
CTP KO-TIP-007          Page 6 
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   11.3  Adverse Event Reporting  ................................ ................................ ....78 
11.3.1  Procedure for Reporting Adverse Events  ................................ ........... 78 
11.3.2  Procedure for Reporting Serious Adverse Events  .............................. 79 
11.3.3  Safety Reporting to Health Authorities, Institutional Review 
Boards  and Investigators  ................................ ................................ .....80 
11.4  Definitions  ................................ ................................ .......................... 80 
11.4.1  Adverse Events  ................................ ................................ ................... 80 
11.4.2  Serious Adverse Event  ................................ ................................ ........ 81 
11.4.3  Events that Do Not Meet the Definition of an SAE  ........................... 81 
11.4.4  Events Not to Be Considered as AEs/SAEs  ................................ .......81 
11.4.5  Abnormal Laboratory Findings and Other Abnormal 
Investigational Findings  ................................ ................................ ......82 
11.5  Adverse Event  Follow -up ................................ ................................ ...82 
12 STATISTICAL CONSIDERATIONS  ................................ ............... 82 
12.1  Statistical Methods  ................................ ................................ .............. 82 
12.1.1  Efficacy  ................................ ................................ ............................... 82 
12.1.2  Safety and Tolerability  ................................ ................................ .......86 
12.1.3 Population Pharmacokinetics  ................................ .............................. 87 
12.2  Subject Population(s) for Analysis  ................................ ..................... 87 
12.2.1  Efficacy Analysis  ................................ ................................ ................ 87 
12.2.2  Safety Analysis  ................................ ................................ ................... 87 
  
12.3  Significance  ................................ ................................ ........................ 88 
12.4  Termination Criteria  ................................ ................................ ........... 89 
12.5  Accountability Procedure  ................................ ................................ ...89 
12.6  Deviation Reporting  ................................ ................................ ............ 89 
13 Regulatory, Ethical, and Study Oversight Considerations  ................. 89 
13.1  Regulatory and Ethical Considerations  ................................ .............. 89 
13.2  Financial Disclosure  ................................ ................................ ........... 90 
13.3  Informed Consent Process  ................................ ................................ ..90 
13.4  Data Protection  ................................ ................................ ................... 90 
13.5  Dissemination of Clinical Study Data  ................................ ................ 91 
13.6  Data Quality Assurance  ................................ ................................ ......91 

Tipifarnib   
CTP KO-TIP-007          Page 7 
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   13.6.1  Data Quality and Integrity Monitoring  ................................ ............... 91 
13.7  Source Documents  ................................ ................................ .............. 92 
13.8  Study and Site Closure  ................................ ................................ ........ 92 
13.9  Publication Policy  ................................ ................................ ............... 92 
14 Guidelines To Be Applied During Infectious Disease Outbreak – 
COVID -19 ................................ ................................ .......................... 92 
14.1  Ensuring Continuity of Safety Reporting  ................................ ........... 93 
14.2  Maintaining Protocol Requirements, Including Schedule of 
Activities  ................................ ................................ ............................. 93 
14.2.1  Clinic Visits  ................................ ................................ ........................ 93 
14.2.2  Clini cal Laboratory Testing  ................................ ................................ 94 
14.2.3  Disruptions for Shipping to Central Laboratories  .............................. 94 
14.3  Informed Consent Process  ................................ ................................ ..94 
14.4  Ensuring Continuity of Drug Supply to Subjects  ............................... 95 
14.5  Managing Restrictions to Site Monitoring by CRAs  .......................... 95 
14.6  Documentation of COVID -19 Related Guidelines or Other  
Measures.  ................................ ................................ ............................ 95 
15 LITERATURE  ................................ ................................ .................... 95 
 
 
 
 
  
 
 
 
 
 
  

Tipifarnib   
CTP KO-TIP-007          Page 8 
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   Tables  
Table 1: Schedule of Events: Pre -screening for for HRAS Mutations  .............................. 21 
Table 2: Schedule of Events: AIM -HN ................................ ................................ ............. 22 
Table 3: Schedule of Events: SEQ -HN ................................ ................................ .............. 25 
 
 
 
 
 
 
 
 
 
Figures  
Figure 1: KO -TIP-007 Study Design  ................................ ................................ ................. 11 
Figure 2: AIM -HN Design  ................................ ................................ ................................ .13 
Figure 3: SEQ -HN Design  ................................ ................................ ................................ .14 
Figure 4: Tipifarnib Activity in HRAS -Mutant HNSCC PDX Models  ............................. 30 
Figure 5: Tipifarnib Activity in Cetuximab -Resistant HRAS -Mutant HNSCC PDX 
Mod els ................................ ................................ ................................ 30 
 
  

Tipifarnib   
CTP KO-TIP-007          Page 9 
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   2 STUDY SYNOPSIS  
TITLE: The AIM -HN and SEQ -HN Study: A 2 Cohort, Non -comparative, Pivotal Study 
Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma 
(HNSCC) with HRAS Mutations (AIM -HN) and the Impact of HRAS Mutations on Response to 
First Line Systemic Therapies for HNSCC (SEQ -HN). 
SPONSOR: Kura Oncology, Inc.  
PROTOCOL NUMBER : KO -TIP-007 
PHASE OF DEVELOPMENT : Pivo tal 
OBJECTIVES:  
Primary Objective:   
• To determine the ob jective response rate (ORR) of tipifarnib in subjects with Head and 
Neck  Squamous Cell Carcinoma  (HNSCC) with HRAS mutations with a VAF ≥20% 
(High VAF population) , as assessed by Independent Review Facility  (IRF) .   
Key Secondary Objective s: 
• To determine the ob jective response rate (ORR) of tipifarnib in subjects with Head and 
Neck  Squamous Cell Carcinoma  (HNSCC) with HRAS mutations of any VAF (All VAF 
population), as assessed by IRF . 
• To determine the Duration of Response (DOR) of tipifarnib in subjects with Head and 
Neck  Squamous Cell Carcinoma  (HNSCC) with HRAS mutations with a VAF≥20% 
(High VAF population), as assessed by IRF.  
• To determine the Duration of Response (DOR) of tipifarnib  in subjects with Head and 
Neck  Squamous Cell Carcinoma  (HNSCC) with HRAS mutations of any VAF (All VAF 
population), as assessed by IRF.  
Other Secondary Objective s for AIM -HN: 
• To determine the anti -tumor activity of tipifarnib in terms of progression free survival, 
and rate of progression free survival at 6 and 9 months in both the high VAF and all VAF 
populations  
• To determine the anti -tumor activity of tipifarnib in terms of overall survival, and rate of 
overall survival at 12 months in bo th the high VAF and all VAF populations  
• To determine the anti -tumor activity of tipifarnib in terms of time to response in both the 
high and all VAF populations  
• To determine the anti -tumor activity of tipifarnib in terms of time to progression (TTP) in 
both the high and all VAF populations  

Tipifarnib   
CTP KO-TIP-007          Page 10  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   • To investigate the safety and tolerability of tipifarnib  according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events v ersion 5.0 (NCI CTCAE 
v5.0) .  
• To investigate the effects of tipifarnib treatment on quality of life measures, including 
EORTC QLQ -H&N35 and EQ -5D-5L. 
• To assess population pharmacokinetics (PK) of tipifarnib in subjects with HNSCC with 
HRAS mutations .   
STUDY DESIGN:  
KO-TIP-007 is an international, multicenter, open -label  singl e- arm pivotal  study. The re are two 
sub-studies, not intended for comparison  (1) an  interventional  open label , single arm , pivotal 
study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM -HN) and  (2) an 
observational study to evaluate  the impact of HRAS mut ations on response to first line systemic  
therapies for HNSCC (SEQ -HN).  
AIM -HN, includes HNSCC subjects with HRAS mutations . AIM -HN subjects will receive 
treatment with tipifarnib  and the outcome will address the primary objective of the KO -TIP-007 
study.  SEQ -HN, is an observational sub-study and includes wild type HRAS HNSCC  subjects  
who consent to provide  first line outcome data and additional follow up. HNSCC patients in 
whom HRAS mutations are identified and who meet eligibility criteria will  be offered 
participation in AIM -HN. HNSCC patients in whom HRAS mutations are  not identified  may 
participate in SEQ -HN only. These patients will be followed and th e comparison of outcomes of 
HRAS mutant and HRAS wild type HNSCC  
 
 

Tipifarnib   
CTP KO-TIP-007          Page 11  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL    
  
KO-TIP-007 will enroll a  total of at  least 305 subjects . AIM -HN, the tipifarnib treatment sub-
study of KO -TIP-007, will investigate the efficacy of tipifarnib in at least 80 subjects  with head 
and neck tumors of confirmed squamous histology with HRAS muta tions.   SEQ -HN, the non-
interventional  observational sub-study , will enroll an additional , at least  225 subjects with HRAS 
wildtype HNSCC tumors . Additional HRAS mutant subjects that consen t to pre -screening, but 
do not enroll in  AIM -HN may have first line treatment data collected as well.  
The study design is shown in  Figure 1 . 
Figure 1: KO -TIP-007 Study Design  
   
• AIM -HN 
AIM-HN will enroll patients with head and neck tumors of confirmed squamous histology with 
HRAS mutations . Subjects must have failed (e.g. tumor progression, clinical deterioration, or 
recurrence ) their most recent prior therapy, and at least one prior line  of systemic platinum -based 
therapy  (the most recent prior and platinum -based  therapy may be the same regimen).  However,  
subjects who, at the judgment of the investigator, are considered not to be candidates to receive 
standard therapy with a platinum -containing regimen  may also be enrolled  (further detailed in 
Section  4.6).  The primary objective of AIM -HN is to determine the ORR of tipifarnib in 
subjects with HNSCC with HRAS  mutations and a VAF ≥20%, as assessed by  IRF.     

Tipifarnib   
CTP KO-TIP-007          Page 12  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   To participate in AIM -HN, all subjects must have measurable disease that meets the criteria for 
selection as a target l esion according to Response Evaluation Criteria in Solid Tumors (R ECIST) 
v1.1. The presence of at least one measurable target lesion per RECIST v1.1 must be confirmed 
by local radiology prior to enrollment. Subjects  without at least one measurable target lesion 
confirmed by local radiology will not be enrolled in to AIM -HN.  
HNSCC d iagnosis by local site pathology laboratory will be used ; however,  all subjects must 
provide pathology  material for central pathology review.  Central c onfirmatio n of pathological 
diagnosis of HNSCC will be required for inclusion  of subjects in the  per-protocol  analysis set .  
Subjects in whom a diagnosis of HNSCC is not confirmed by central review may continue to 
receive study treatment  and will be included in the modified intent -to-treat (mITT) analysis set .  
All AIM -HN enrolled subjects must have a known missense HRAS tumor mutation based on  
centralized testing  or other HRAS test used by the trial site that has been approved by the  
Sponsor. HRAS status  should be assessed on tumor obtained subsequent to the most recent pri or 
therapy in order to obtain  the most recent tumor biology; if tumor tissue that does not meet this 
criterion must be used (e.g. risk of biopsy is too high, patient refuses  new biopsy ), the 
investigator  should document  the reason . If several samples are a vailable, HRAS testing should 
be performed in the most recently obtained tumor sample.  To facilitate development of 
appropriate diagnostic testing, all subjects must provide enough tumor material for confirmation 
of HRAS status by central lab . This tissue should be from the same source as that used for pre -
screening, or the reason that is not possible documented.  Subjects who were enrolled in the 
study based on HRAS mutation using  a Sponsor approved test, but in whom a missense HRAS 
mutation is  not confirmed by central laboratory , may continue to receive study treatment.  SEQ -
HN subjects who were initially identified as w ild type HRAS but in whom a n HRAS mutation is 
later detected during the course of their standard therapy, will become eligible to screen for  
AIM -HN.   
AIM -HN e nrolled s ubjects will receive tipifarnib administered at a dose of 600 mg, orally with a 
meal  twice a day (bid) for 7 days in alternating weeks (Days 1 -7 and 15 -21) in 28-day cycles.  
Stepwise 3 00 mg dose reductions to contr ol treatment -related, treatment -emergent toxicities are 
described in Section  8.1.2 .  In the absence of unmanageable toxicities, subjects may continue to 
receive tipifarnib treatment until  disease progression.  If a complete response is observed, and 
subject continues to tolerate therapy , therapy with tipifarnib will be maintained for at least 6 
months beyond the start of  response.  
Tumor assessment  for the primary analysis will be performed  by the IRF according to RECIST 
v1.1 and assessed by an Independent Data Monitoring Board (IDMB).  Investigator assessment 
of tumor response will also be collected  and reported  as a supportive analysis . Assessments will 
be performed at screening and approx imately every 8 weeks for  the first 12 months  of a subject’s 
participation in AIM -HN; thereafter, tumor response assessment should occur  approximately 
every 12 weeks until disease progression .  Radiological assessments will be discontinued at the 
time of t umor progression.  If the subject initiates a new anticancer therapy  without evidence of 

Tipifarnib   
CTP KO-TIP-007          Page 13  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   disease progression by RECIST v1.1, tumor scans should continue until there is evidence of 
disease  progression  unless withdrawal of subject’s consent to study procedures .  Local 
investigator evaluation of tumor assessment will guide on -study treatment decisions, including 
decisions to stop study treatment due to progressive disease.   
Upon disease progression, all subjects will be followed approximately every 12  weeks for 
survival and the use of subsequent therapy until either death or End of Study (up to 2 years after 
the enrollment of the last study subject  in AIM -HN, see Section 6.7.1 ), whichever occurs first.  
All subjects will be  followed -up for safety  through  the End of Treatment visit which occurs 
approximately 30 days after treatment discontinuation  or immediately before the administration 
of another anticancer treatment , whichever occurs first . Additional safety follow -up may be 
conducted if unresolved toxicity is present at th is End of Treatment visit.  The IDMB will provide 
periodic evaluations of safety and other data to ensure adequate benefit/risk  as well as  the 
validity and scientific merit of the study.  
An overview of the AIM -HN sub-study design is shown in  Figure 2 . 
Figure 2: AIM -HN Design  
   
• SEQ -HN 
SEQ -HN is an observational sub-study  
  Demographics, 
disease history, information on prior anti -cancer treatments and outcomes to prior treatments for 
HNSCC will be collected from  all enrolled subjects . At least approximately 225 c ontrol patients 

Tipifarnib   
CTP KO-TIP-007          Page 14  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   with HNSCC without known HRAS mutations , will be enrolle d into  SEQ -HN.  As part of their 
participation in SEQ -HN, patients will be followed up through initiation of second line therapies,  
death or consent withdraw , whichever occurs first . A subset  of the approximate 225 control 
patients  will be matched to the HRAS mutant  subjects to the greatest extent possible according to 
pre-defined patient characteristics. If necessary, a dditional follow up of the matched HRAS 
wildtype HNSCC patients enrolled into SEQ -HN may continue until all AIM -HN objectives are 
completed and KO -TIP-007 end of study is reached. Control patients with HNSCC with  wildtype  
HRAS will not receive tipifarnib treat ment as part of their participation in SEQ -HN; however, 
they may be compensated for their participation in data collection, blood sampling, screening 
and follow up procedures according to institutional guidelines.  
An overview of the SEQ -HN design is shown in Figure 3 . 
Figure 3: SEQ -HN Design   
  
NUMBER OF SUBJECTS PLANNED :  
In AIM -HN, a t least 80 subjects  meet ing all criteria for inclusion in the per -protocol analysis set  
will be enrolled .  
Subject criteria for inclusion in the per -protocol analysis set include: received at least one dose of 
tipifarnib, confirmed measurable disease at baseline per RECIST v1.1 by IRF, confirmed 
diagnosis of HNSCC by central pathology review , and at least one p ost baseline disease 
assessment (e.g. tumor assessment visit ). In SEQ -HN, approximately  an additional  225 patients 
with HNSCC but without detected HRAS mutations will also be enrolled . A subset of the  
wildtype  HRAS subjects will be selected as a matched -control subset to those  subjects with:  
• HRAS mutant tumors  enrolled as part of AIM -HN,   

Tipifarnib   
CTP KO-TIP-007          Page 15  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   • HRAS mutant tumors that do not enroll in AIM -HN, but have 1L data collected 
during  the pre-screening period  
SUBJECT SELECTION :  
Inclusion Criteria : AIM -HN 
For i nclusion of a subject in the tipifarnib treatment portion of the study  (AIM -HN), all of the 
following inclusion criteria must be fulfilled . If a subject does initially not meet any inclusion 
criteria, the subject may be re -screened at a later time :  
1. At least 18 years of age . 
2. Histologically confirmed head and neck cancer  (oral cavity, pharynx, larynx, sinonasal , 
nasopharyngeal,  or unknown primary)  of squamous histology  not amenable to local therapy 
with curative intent (surgery or radiation therapy with o r without chemotherapy). Enrol lment 
may proceed with local diagnosis but all subjects must consent to provide tumor tissue for a 
central pathology review.  
3. Documented treatment failure from most recent prior therapy (e.g. tumor progression, 
clinical deterio ration, or recurrence) , and from at least one prior platinum -containing 
regimen , in any treatment setting . The most recent prior and platinum -based  therapy may be 
the same regimen. Those subjects  who, at the judgment of the investigator, are considered 
clinically unsuitable to receive standard platinum -containing regimen , may also be enrolled 
and the reason  for clinical  unsuitability recorded.  There is no limit on the number of prior 
lines of therapy.  
4. Known tumor missense HRAS mutation  detected by  Next Generation Sequencing (NGS) or 
any other methodology approved by the Sponsor . Variant allele frequency (VAF) needs to be 
determined and must be available.  HRAS status should  be assessed on tumor tissue obtained  
subsequent to the most recent prior therapy  so that the most  accurate tumor biology is 
evaluated . If tumor tissue that does not meet this criterion must be used (e.g. risk of new 
biopsy is too high, patient refuses new biopsy), the investigator should document the reason.  
Enrol lment may proceed with the identification of a missense HRAS mutation using a test 
preferred by the investigator  and approved by the Sponsor  during pre -screening , but all 
subjects must consent to provide tumor tissue for central HRAS confirmation .  
 
 
5. Measurable disease by RECIST v1.1 (Appendix I) that meets the criteria for selection as a 
target lesion according to RECIST v1.1.  The presence of at least one measurable  target 
lesion  per RECIST v1.1  must be confirmed by local radiology prior to subject entry.  
6. At least 2 weeks or 5 half-lives, whichever is longer, since the last systemic therapy regimen 
prior to Cycle 1 Day 1.  Last dose of any prior checkpoint inhibitor therapy must have been 

Tipifarnib   
CTP KO-TIP-007          Page 16  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   administered at least 2 weeks prior to C1D1 . Subjects must have recovered to NCI CTCAE 
v5.0 < Grade 2 from all acute toxicities (excluding Grade 2 toxicities that are not considered 
a safety risk by the Sponsor and Investigator) or toxicity must be deemed irreversible by the 
Investigator.  
7. At least 2 weeks since last radiotherapy. Subjects must have recovered from all acute  
toxicities from radiotherapy.  
8. ECOG p erformance status of 0 -1 (Appendix II ). 
9. Acceptable liver function:  
a) Bilirubin  1.5 times upper limit of normal (x ULN) . 
b) AST (SGOT) and ALT (SGPT)  1.5 x ULN . 
The subject must meet /continue to meet  these criteria at the time of first dosing , as 
confirmed by analysis within 72 hours  of C1D1.  
10. Acceptable renal function with either serum creatinine  1.5 x ULN  or a calculated creatinine 
clearance ≥ 60 mL/min using the Cockcroft -Gault or Modification of Diet in Renal Disease 
(MDRD ) formulas.  
The subject must meet/continue to meet these criteria at the time of first dosing, as 
confirmed by review of analysis perfo rmed within 72 hours of C1D1.  
11. Acceptable hematologic status:  
a) ANC  1000 cells/μL.  
b) Platelet count  75,000/μL.  
c) Hemoglobin  8.0 g/dL.  
The subject must meet/continue to meet these criteria at the time of first dosing, as 
confirmed by review of analysis performed within 72 hours of C1D1.  
12. Female subjects must be:  
a) Of non -child -bearing potential (surgically sterilized or at least 2 years post -
menopausal); or  
b) If of child -bearing potential, subject must use a highly effective method of 
contraception, such as combined (estrogen and progestogen containing) hormonal 
contraception associated with inhibition of ovulation, progestogen -only hormonal 
contraception assoc iated with inhibition of ovulation, intrauterine device, 
intrauterine hormone -releasing system, bilateral tubal occlusion, vasectomised 
partner or sexual abstinence.  Both females and male subjects with female 
partners of child -bearing potential must agree  to use a highly effective method of 
contraception from the first dose of tipifarnib , during  tipifarnib treatment , and at 

Tipifarnib   
CTP KO-TIP-007          Page 17  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   least 28 days after last dose of  tipifarnib  for females and 90 days for males. 
Female subjects must have a negative serum or urine pre gnancy test within 72 
hours prior to start of trial medication.  
c) Not breast feeding at any time during the study.  
13. Written and voluntary informed consent understood, signed and dated . 
Exclusion Criteria: AIM -HN  
If a subject initially meets any exclusion criteria, the subject may be re -screened at a later time . 
1. Has disease that is suitable for local therapy administered with curative intent . 
2. Histologically confirmed salivary gland , thyroid, (primary) cutaneous squamous  or 
nonsquamous histologies (e.g. mucosal melanoma) .  
3. Known additional malignancy that is progressi ng or requires active treatment  (excluding 
non-melanoma skin cancer, adjuvant hormonal therapy for breast cancer and hormonal 
treatment for castration sensitive prostate cancer).  
4. Ongoin g treatment with an anticancer agent not contemplated in this protocol  (excluding 
adjuvant hormonal therapy for breast cancer and hormonal treatment for castration sensitive 
prostate cancer) . 
5. Prior treatment (at least 1 full treatment cycle)  with a  farnesy ltransferase inhibitor  (FTI) . 
6. Any use of investigational therapy within 2  weeks of Cycle 1 Day 1  (C1D1)  or 5 half -lives 
(whichever is longer ). Last dose of any prior checkpoint inhibitor  therapy  must have been 
administered  at least 2 weeks prior  to C1D1 . 
7. Received treatment for unstable angina within prior year, myocardial infarction within the 
prior year, cerebro -vascular attack within the prior year, history of New York Heart 
Association grade III or greater congestive hea rt failure, or current serious cardiac arrhythmia 
requiring medication except atrial fibrillation.  
8. Non-tolerable  Grade 2 or ≥  Grade 3 neuropathy or evidence of unstable neurological 
symptoms within 4 weeks of Cycle 1 Day 1. Non -tolerable  Grade 2  toxicities  are defined as 
those with moderate symptoms that the subject is not able to endure for the conduct of 
instrumental activities of daily life or that persists ≥ 7 days.  
9. Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, wit hout 
complete recovery.  
10. Active, uncontrolled bacterial, viral,  or fungal infections requiring systemic therapy , 
including  known history of infection with human immunodeficiency virus  or an active 
infection with hepatitis B or hepatitis C.  

Tipifarnib   
CTP KO-TIP-007          Page 18  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   11. Subjects who have exhibited allergic reactions to tipifarnib or structural compounds similar 
to tipifarnib or to its excipients. This includes hypersensitivity to imidazoles, such as 
clotrimazole, ke toconazole, miconazole and others in this drug class. Subjects  with 
hypersensitivity to these agents will be excluded from enrol lment.  
12. Required use of concomitant medications classified as s trong inhibitors or inducers of 
cytochrome P450 3A4 ( CYP3A4 , Table 1 1) or UDP -glucuronosyltransferase (UGT).    
13. Concomitant disease or condition that could interfere with the conduct of the study or that 
would, in the opinion of the investigator, pose an unacceptable risk to the subject in this 
study.  
14. Female subjects who are pregnant or lactating.  
15. Unwillingness or inability to comply with the study protocol for any reason.  
Inclusion Criteria : SEQ -HN  
For inclusion of a subject in the noninterventional portion of the study  (SEQ -HN), all of the 
following inclusion criteria must be fulfilled:   
1. At least 18 years of age . 
2. Histologically confirmed head and neck cancer (oral cavity, pharynx, larynx, sinonasal, 
nasopharyngeal, or unknown primary) of squamous histology .   
3. HRAS wildtype (i.e. have no identified  tumor missense HRAS mutation ) determined by a 
test preferred by the investigator  and approved by the Sponsor or through central HRAS 
testing.   
4. Will or has received at least one system ic anti -cancer therapy for recurrent or metastatic 
HNSCC for which there is availabl e outcome information in terms of ORR, or can be 
determined based on the subject’s records. Subjects  who have not yet received or completed 
at least one systemic anti -cancer therapy for recurrent or metastatic HNSCC must consent to 
the collection of treatment outcome information and additional fol low up contact  in order to 
participate in the SEQ -HN porti on of the study .  
5. Written and voluntary informed consent understood, signed and dated . 
Exclusion Criteria : SEQ -HN 
1. Histologically confirmed salivary gland , thyroid, (primary) cutaneous squamous  or 
nonsquamous histologies (e .g. mucosal melanoma) .  
2. Concomitan t disease or condition that could interfere with the conduct of the study or that 
would, in the opinion of the investigator, pose an unacceptable risk to the subject in this 
study.  
3. The subject has legal incapacity or limited legal capacity.  

Tipifarnib   
CTP KO-TIP-007          Page 19  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   STATISTICAL METHODS:  
AIM -HN: 
AIM -HN is based on a two -stage minimax design with a hypothesized ORR of p1=30% for 
tipifarnib and a minimal or uninteresting ORR of p0=15%.   The primary efficacy analysis , based 
on the evaluation of a 2 -sided 95% confidence in terval around the ORR,  will be performed on 
the mITT population comprised of all enrolled subjects who have received at least one dose of 
tipifarnib  through their participation in AIM -HN. The mITT will also be used for all safety 
analyses.  
AIM -HN plans to enroll at least 80 subjects  with HRAS mutations   
 
meeting all criteria for inclusion in the per -protocol analysis set.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
The final analysis will be conducted on all subjects in the mITT analysis population set  as well 
as the  planned 80 subjects in the per -protocol analysis set .   

Tipifarnib   
CTP KO-TIP-007          Page 20  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL     

Tipifarnib   
CTP KO-TIP-007          Page 21  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   STUDY ASSESSMENTS:  
Table 1: Schedule of Events: Pre-screening for HRAS Mutations  
Upon determination of HRAS mutational status, subject will proceed to cohort -specific screening 
procedures for participation in AIM -HN (HRAS mutant HNSCC subjects, refer to  Table 2 ) or SEQ -
HN (HRAS wildtype HNSCC subjects, refer to  Table 3 ) 
 
1. Pre-screening for HRAS mutation procedures  can be done at any time prior to enrollment  in AIM -HN or SEQ -HN. 
2. Required for subjects with unknown HRAS mutational status.  Tumor  tissue for HRAS testing should be on a biopsy taken 
subsequent to the most recent prior therapy so that the most current tumor biology is assessed; if a biopsy meeting this 
criterion is not possible, the reason  must be documented . Detailed tumor sample co llection, storage and shipping procedures 
will be provided in a separate lab manual.  Results must be obtained prior to enrolment in either cohort.  Further collection of 
tissue may be requested from wildtype patients.  
  
4. Information to be collected from all subjects: anatomical biopsy site, date of sampling and setting (e.g. primary, locally 
advanced, metastatic lesion), HRAS mutation in sample  including  variant allele frequency  or HRAS wildtype status .  
Additionally, the  test platform (e.g. NGS  gene panels , PCR, other)  will be collected if performed at the clinical site or 
reference laboratory employed by the clinical site using a Sponsor approved test . 
5. Demographics and disease history including primary diagnosis (date of initial diagnosis, stage of disease at diagnosis, 
anatomical disease site(s) at diagnosis), current stage of disease, smoking and betel nut exposure history, alcohol use, HPV 
status and other relevant medical history. Prior anti -cancer therapy for HNSCC including name, dates (start, end), treatment 
outcome (response and resp onse criteria), duration of response, date of progression. Additionally, information will be 
collected specific to first line systemic treatment for recurrent or metastatic HNSCC. Information will also be collected on 
prior cancer surgery for HNSCC includi ng date(s) of surgery. Information will be collected on prior/current radiological 
treatments for HNSCC including anatomical site(s) and date(s) of radiation treatment. In subjects who have not yet received 
or completed first line systemic treatment for re current or metastatic HNSCC, first line systemic treatment information 
(anatomical disease site, performance status, names and dates of treatment, treatment outcome, duration of response and date 
of progression) will be collected through follow -up contact.   
 
 
 
 
 
 
 
 
  Activity  Pre-Screening 1 
ICF for Pre-screening for HRAS mutation s  X  
Tumor tissue for HRAS mutational testing 2 X 
HRAS mutation information 4 X 
Collection of first line efficacy/response data  and demographics 5 X 

Tipifarnib   
CTP KO-TIP-007          Page 22  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   Table 2: Schedule of Events : AIM -HN 
Activity  Screenin
g1 Day 1 
(± 2d)  of 
every 
Cycle  Day 7 
(± 2d)  of 
Cycle 1 18 Tumor 
Response 
Assessme
nt 
Visit 2 End of 
Treatme
nt Visit 3 Follo
w Up 
Visit 4  Follo
w Up 
Conta
ct 
AIM -HN ICF/PIC, form s X       
Completion of inclusion/ 
exclusion criteria 
evaluation and submission 
of enrollment form to 
Sponsor or their designee  X   
    
Confirmation of 
measurable disease per 
RECIST v1.1 by local 
radiology  X   
    
Demographics and Disease  
History 5  X       
Prior anti -cancer therapy 
for HNSCC 6 X       
Buccal swab 7 X       
Concomitant medications  X X  X X X8  
AE assessment 9 X X  X X X8  
Complete physical 
examination  X10    X   
Symptom based physical 
exam   X11      
Height  X10       
Weight  X10 X11   X   
Vital signs 12 X10 X11   X   
Electrocardiogram  X10       
ECOG performance status  X10 X11   X   
Pregnancy test 14 X15 X16   X   
Serum chemistry 17 X10 X11 X18  X   
Hematology 17 X10 X11 X18  X   
Coagulation 17 X10       
Urinalysis 19 X10       
Radiographic Imaging, 
transfer of tumor scans and 
related clinical data to 
IRF 20 X13   
X21 X22 X23  
Tumor tissue for HRAS 
mutational testing and 
pathology confirmation at a 
central lab 31, 32 X   
    

Tipifarnib   
CTP KO-TIP-007          Page 23  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   1. Screening evaluations will be completed within 4 weeks (28 days) of Cycle 1 Day 1. Evaluations performed as part of the 
standard of care within 28 days of dosing (prior to study specific consent signature ) do not need to be repeated .  
2. Tumor response assessment should occur approximately every 8 weeks (± 5 days) for the first 12 months of a subject’s 
participation in AIM -HN; thereafter, tumor response assessment should occur approximately every 12 weeks  (± 5 days) 
until disease progression.  
3. An End of Treatment visit will be conducted approximately  30 days (± 7 days) from the last dose of tipifarnib or 
immediately before the initiation of any other anticancer therapy , whichever occurs first . 
4. Follow up visit re quired only for subjects who terminated treatment for reasons other than disease progression  and should 
occur approximately every 8 or 12 weeks  (± 5 days) until disease progression . 
5. Demographics and d isease  history including primary diagnosis  (date of initial diagnosis, stage of disease at diagnosis, 
anatomical disease site(s) at diagnosis), current stage of disease, smoking and betel nut exposure history, alcohol use, HPV 
status and other relevant medical history.  
6. Prior anti-cancer therapy fo r HNSCC including name, dates (start, e nd), treatment outcome (response and response criteria), 
duration of response, date of progression. Additionally, information will be collected specific to first line systemic treatment 
for recurrent or metastatic HNS CC.  Information will also be collected on prior cancer surgery for HNSCC including date (s) 
of surgery.  Information will be collected on prior/current radiological treatments for HNSCC including anatomical site(s) 
and date(s) of radiation treatment.  
7. Bucca l swabs will be collected at screening for CXCL12 SNP testing and as a control sample for the analysis of tumor 
mutations using kits provided by the Sponsor. If swabs are not collected during screening for any reason, collection can be 
conducted at any tim e during the study.  Detailed buccal swab  collection, storage and shipping procedures will be provided 
in a separate lab manual.  
8. Assessments of adverse events and concomitant medications may also be conducted if adverse events were not resolved at 
the time of the End of Treatment visit.  
9. Assessed from signing the AIM -HN ICF through  approximately  30 days after treatment discontinuation. Additional 
assessments may be performed until AE resolution or the AE is deemed irreversible by the Investigator.  
10. Evaluation should be performed within 14 days prior to the first administration of study drug.  Lab i nvestigations 
(hematology and serum chemistry) should be repeated and reviewed within 72 hours of first dosing and continued eligi bility 
for dosing confirm ation . 
11. Assessment on Cycle 1 Day 1 is to occur prior to tipifarnib dosing.  Labs drawn within 72 hours  of dosing may be used for 
C1D1. Labs must be reviewed prior to dosing to confirm subject remains eligible.  
12. Vital signs to include: heart rate, blood pressure and temperature . 
13. In addition to baseline tumor scans that are to be obtained within 28 days prior  to Cycle 1 Day 1, e fforts should be made to 
obtain historical scans to document tumor progression  on prior line of therapy for transfer to the IRF . All efforts to submit 
these scans by the first tumor response assessment (approximately 8 weeks following Cycle 1 Day 1)  should be made .  
These historical scans should include the scans that demonstrate progression that occurred on the prior regimen and a prior 
scan demonstrating the nadir p rior to the progression.   
14. Pregnancy testing will be performed in females of child -bearing potential and testing may be performed on urine or serum.  
If a positive urine pregnancy test is obtained, a confirmatory serum pregnancy test should be conducted.   If confirmatory test 
is positive, subject must terminate tipifarnib treatment immediately and follow pregnancy reporting guidelines outlined in 
the protocol.  Pregnancy testing will be performed locally at the clinical site or its reference laboratory . 
15. Fema le subjects  of child -bearing potential  must have a negative serum or urine pregnancy test within 72 hours prior to start 
of study medication (Cycle 1 Day 1).     
16. Assessment  to begin starting at Cycle 2.  
17. Fasting for laboratory testing is not required. Laboratory tests may be conducted at additional time points if deemed 
necessary by the Investigator. Samples will be analyzed locally at the clinical site or its reference laboratory. Laboratory 
assessments m ay be repeated if values are borderline to inclusion level or may change due to best supportive care measures.  
Serum chemistry should include: Glucose, Blood Urea Nitrogen (or Urea ), Creatinine, Sodium, Potassium, Chloride, 
Calcium, Magnesium, Phosphorus,  Total Protein, Albumin, Total Bilirubin, Alkaline Phosphatase, ALT, AST, Gamma -
Glutamyltransferase, Lactate Dehydrogenase , Bicarbonate or total CO 2 (optional, as clinically indicated) . Hematology Tipifarnib administration 28   X      
Drug accountability and 
diary review   X16   X   
Collection of survival and 
anticancer treatment 
information 29    
   X 
QoL questionaires 34 X X   X   

Tipifarnib   
CTP KO-TIP-007          Page 24  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   should include: White Blood Cell Count, Red Blood Cell Coun t, Hemoglobin, Hematocrit, Platelet Count, Neutrophils, 
Lymphocytes, Monocytes, Eosinophils, Basophils . Coagulation should include: APTT , PT/INR.   
18. Laboratory tests for C1D7  are required for Denmark,  and are optional/ should be performed based upon clinical  judgment for 
all other regions . 
19. Macroscopic assessment of the amount of protein, glucose, white blood cells and blood will be conducted in the urine 
samples. If abnormalities are noted, these will be recorded , and a microscopic urinalysis conducted and recorded. If at any 
time, the subject’s serum creatinine is ≥ Grade 2, then a serum chemistry, microscopic urinalysis including the measurement 
of protein, glucose, blood, and white blood cells will be conducted.  If abnormalities are noted, then spot urine sodium, 
protein and creatinine should be performed to assess fractional sodium excretion (plasma creatinine x urine sodium / plasma 
sodium x urine creatinine) and urine protein/creatinine ratio (urine protein mg /urine creatinine mg ratio). Samples will be 
analyzed locally at the clinical site or its reference laboratory.  
20. CT scan with a contrast agent is the preferred imaging method and the same technique should be used at baseline and post -
treatment assessments. CT scan coverage at screening  should encompass scans of the  neck (including the skull base), chest 
and abdomen (including the liver and adrenals) .  Any other areas of disease involvement should be scanned based on the 
subject’s signs and symptoms. If subje cts are allergic to IV contrast, MRI scans or non -contrast CT may be used. Subjects 
with contrast allergy or renal insufficiency may use non -contrast CT or MRI, whichever is required to adequately assess all 
disease.  The one exception where MRI would not b e recommended is for the evaluation of parenchymal lung metastases.  In 
this instance, CT would be preferred.  If imaging of the brain is indicated, MRI of the brain with and without gadolinium 
should be performed for optimal evaluation of the brain.  If M RI is medically contraindicated, CT of the brain with and 
without contrast would be suggested.  Guidelines for imaging and instructions for transmission of the images to the IRF will 
be provided to each study site.  
21. CT scans will be performed at least once approximately every 8 weeks (± 5 days) for 12 months , thereafter once 
approximately every 12 weeks (± 5 days) until disease progression.  The imaging schedule (every 8  weeks or every 12  
weeks) should be maintained regardless of dosing delays or additional i maging assessments performed.  
22. Scans at the End of Treatment visit : Applies only for subjects who terminated treatment for reasons other than disease 
progression.  In these subjects, im aging should be performed at the End of Treatment visit if not done within the prior 8 
weeks or if a tumor assessment is required for the confirmation of response.  
23. Subjects who discontinue treatment for reasons other than disease progression should continu e tumor assessments until 
disease progression . Tumor assessments may continue upon initiation of another anticancer therapy  unless  withdrawal of 
subject’s consent to study  procedures .   
  
 
 
  
 
 
  
  
 
 
 
  
 
28. Subjects  will receive tipifarnib starting at 600 mg orally bid with food on days 1 -7 and 15 -21 of 28-day treatment cycles.  
29. Upon disease progression, follow up contact with the subject and/or caregiver(s) (e.g. electronic technology -based, 
telephone or in p erson)  is to occur approximately every 12 weeks (± 1 week) for survival and the use of subsequent therapy 
until either death or End of Study (up to 2 years since the enrollment of the last study subject  in AIM -HN, see Section  
6.7.1 ), whichever occurs first. Information on survival and subsequent anticancer therapy  for HNSCC  will be collected  
including name, dates (start, end), treatment outcome (response and response criteria), duration of re sponse, date of 
progression. Information will also be collected on subsequent cancer surgery(ies) for HNSCC including date of surgery.  
Information will be collected on subsequent radiological treatments for HNSCC including anatomical site(s) and date(s) o f 
radiation treatment.  
  
   
31. Tumor tissue  for central review /confi rmation , preferably from the same tiss ue sample used for Pre -screening HRAS 
mutational testing, must be confirmed as available prior to Cycle 1 Day 1 of AIM -HN. Whenever possible, sample should be 
sent to Sponsor (or designee) prior to Cycle 1 Day 1.  
32. Detailed tumor sample collection, storage and shipping procedures will be provided in a separate lab manual.  
  
   
34. EORTC QLQ -H and N35 and EQ -5D-5L (Appendix III ) quality of life questionnaires will be completed at baseline, 
monthly on treatment, and at the End of Treatment visit .  

Tipifarnib   
CTP KO-TIP-007          Page 25  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   Table 3: Schedule of Events : SEQ -HN 
 
1. Screening and study enrollment may occur during the same visit . 
2. On study visit is to occur between weeks 16 – 24 from the subject’s enrollment in SEQ -HN.  If a subject experiences disease 
progression or initiates second line therapy prior to weeks 16 - 24, the blood sample for HRAS mutational analysis should 
be collect ed at that time.     
3. Follow up contact with the subject and/or caregiver(s) (e.g. electronic technology -based, telephone or in person) is to occur 
approximately every 12 weeks (± 1 week) from the time of study enrollment  through  initiation of second line therapy  
consent withdraw, or completion of AIM -HN, whichever occurs first . Regimen and start date  of second line therapy initiated 
will be recorded. Additional follow up of the matched HRAS wildtype HNSCC patients enrolled into S EQ-HN may 
continue until all AIM -HN objectives are completed and KO -TIP-007 end of study is reached.  
4. Demographics and d isease  history including  primary diagnosis  (date of initial diagnosis, stage of disease at diagnosis, 
anatomical disease site(s) at diagnosis), current stage of disease, smoking and betel nut exposure history, alcohol use, HPV 
status and other relevant medical history . 
5. Prior anti -cancer therapy fo r HNSCC including name, dates (start, end), treatment outcome (response and response criteria), 
duration of response, date of progression. Additionally, information will be collected specific to first line systemic treatm ent 
for recurrent or metastatic HNS CC. Information will also be collected on prior cancer surgery for HNSCC including date(s) 
of surgery. Information will be collected on prior/current radiological treatments for HNSCC including anatomical site(s) 
and date(s) of radiation treatment.  In subj ects who have not yet received or completed first line systemic treatment for 
recurrent or metastatic HNSCC, first line systemic treatment information (anatomical disease site, performance status, 
names and dates of treatment, treatment outcome, duration o f response and date of progression) will be collected through 
follow -up contact.   
  
 
 
 
  Activity  Screening 1 Study 
Enrollment 1 On Study Visit : 16 – 24 weeks  since 
enrollment  in SEQ -HN or at disease 
progression, whichever occurs first 2 Follow Up 
Contact 3 
ICF for participation in 
SEQ -HN X    
Inclusion/ exclusion 
criteria evaluation  X    
Demographics and d isease  
history 4   X   
Prior anti -cancer therapy 
for HNSCC 5  X  X 

Tipifarnib   
CTP KO-TIP-007          Page 26  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   3 LIST OF ABBREVIATIONS  
 
ALCOA+  Data integrity principles of attributable, legible, contemporaneous, original, accurate, 
complete, consistent, enduring and available.  
AE adverse event  
ALT  alanine aminotransferase  
ANC  absolute neutrophil coun t 
APTT  activated partial thromboplastin time  
AST  aspartate aminotransferase  
bid twice a day  
BIW  twice weekly  
BSC  best supportive care  
COVID -19 coronavirus disease 2019  
CR complete response  
CSR  clinical study report  
CT computer tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CYP  cytochrome P450  
DLT  dose limiting toxicity  
DOR  duration of response  
DPA  Data Protection Act 
ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group 
eCRF  electronic c ase report form  
FDA  Food and Drug Administration  
FTase  farnesyltransferase  
FTI farnesyltransferase inhibitor  
GCP  Good Clinical Practice  
HDPE  high density polyethylene  
HIPAA  Health Insurance Portability and Accountability Act  
HIV/AIDS  human immunodeficiency virus infection and acquired immune deficiency syndrome  
HPV  human papilloma virus  
HNSCC  head and neck squamous cell carcinoma  
HRAS  Harvey rat sarcoma virus gene homolog  
IC50  half maximal inhibitory concentration  
ICF informed consent form  
ICH International Conference on Harmonization  
IDMB  Independent Data Monitoring Board  
IEC Independent Ethics Committee  
IP investigational product  
IRB Institutional Review Board  
IRF Independent Review Facility  
KRAS  Kirsten rat sarcoma virus gene homolog  
MDRD  modification of diet in renal disease  
MDS  myelodysplastic syndromes  
MeDRA  Medical Dictionary for Regulatory Activities  
mITT  modified intent -to-treat 
MRI  magnetic resonance imaging  
MTD  maximum tolerated dose  
NCI National Cancer Institute  
NGS  next generation sequencing  
NRAS  neuroblastoma RAS viral oncogene homolo g 

Tipifarnib   
CTP KO-TIP-007          Page 27  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   NSCLC  non-small cell lung cancer  
OR objective response  
ORR  objective response rate  
OS overall survival  
PDX  patient derived xenograft  
PFS progression free survival  
PIC patient informed consent  
PK pharmacokinetic  
PR partial response  
PT/INR  prothrombin time/international normalized ratio  
QW once weekly  
RECIST  response evaluation criteria in solid tumors  
SAE  serious adverse event  
SAP statistical analysis plan  
SCLC  small cell lung cancer  
SGOT  serum glutamic oxaloacetic transaminase  
SGPT  serum glutamic pyruvic transaminase  
SUSAR  Suspected Unexpected Serious Adverse Reactions  
TTP time to progression  
UGT  UDP -glucuronosyltransferase  
ULN  upper limit of normal  
US United States  
v version  
VAF  variant allele frequency  
 
 
  

Tipifarnib   
CTP KO-TIP-007          Page 28  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   4 BACKGROUND  
Brief information on tipifarnib is presented in this section; more extensive information is 
provided in the Tipifarnib Investigator’s Brochure . 
4.1 Investigational Agent  
Tipifarnib (R115777; Zarnestra™)  
4.2 Study Rationale  
4.2.1 Head and Neck Squamous Cell Carcinoma  
Head and nec k squamous cell carcinoma accounts for more than 550,000 cases annually, 
worldwide  (Leemans 2011 ) with incidence rates of certain subtypes (oropharyngeal) on the rise  
(Chaturvedi 2011 ). Carcinogen (tobacco, alcohol) exposure and infection with the human 
papillomavi rus (HPV) are described as the two  major eti ological causes of HNSCC . Differences 
in prognoses have been reported for HPV -negat ive and HPV -positive HNSCC , with HPV 
negativity  being associated with worse clinical outcome  (Leemans 2011 ). 
Genomic structural alterations are commonly seen i n HNSCC . Both HPV -positive and HPV -
negative tumors harbor amplific ations of 1q, 3q, 5p and 8q and deletions of 3p,  5q, and 11q . The 
amplification of 3q26/28 region containing the squamous  lineage transcription factors TP63 and 
SOX2, and the PIK3CA oncogene is seen in both  HPV -positive and HPV -negative tumors, but 
more fr equently in the HPV -positive subtype . In HPV -positive tumors, recurrent deletions in 
TRAF3 and 11q , including the ATM1  region,  and focal amplification of E2F1 are also seen , but 
9p21.3 , containi ng CDKN2A, is usually intact . In c ontrast, in HPV -negative tum ors 9p21.3 is 
commonly deleted while 11q13 , containing ANO1, CCND1 and FADD , and  11q22 , containing 
BIRC2 and YAP1 are amplified ( Aung 2016 ).  
From a biological perspective, the recurrent CDKN2A deletions and CCND1 amplification seen 
in HPV -negative tumors and E2F1 amplifications in HPV -positive tumors indicate that loss  of 
cell cycle regulation is a fundamental event in HNSCC carcinogenesis. Also, the importance of 
the RAS/MAPK and PI3K/AKT pathway s, particularly in HPV -negative HNSCC,  is highlighted 
by EGFR amplification, HRAS mutation and PIK3CA related alterations ( Aung 2016 ). Of note, 
it has been suggested that HRAS signals almost exclusively through PI3K -AKT and not through 
MAPK in HNS CC ( Endhardt 2014 ). TP53 is also frequently mutated in HPV -negative  cases 
whereas TP53 alterations are infrequent in HPV -positive tumors. However, a  small subset of 
HPV -negative , frequently  oral cavity , carcinoma s do not hav e TP53 mutations and harbo r 
activating HRAS mutations with or without inactivating CASP8 mutations , constituting a distinct 
subset of HNSCC ( TCGA 2015 ).  
The relevance of HRAS mutations is highlighted by the availability of farn esyltransferase 
inhibitors (FTIs).  Although FTI s prevent more than 140 potential proteins from getting 

Tipifarnib   
CTP KO-TIP-007          Page 29  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   farnesylated, the function of many of these proteins is kept intact due to the compensative 
prenylation through type 1 geranylgeranyl transferase ( Baines 2011 ; Berndt 2011 ; Takashima 
2013 ).  Among RAS isoforms, inhibition of the farnesylation of KRAS and NRAS leads to their 
geranylgeranylation and unchanged membra ne localization.  HRAS cannot be 
geranylgeranylated and its membrane localization and cellular function is suppressed by FTIs 
(Whyte 1997 ).  Consequently, HRAS driven tumors are very sensitive to FTIs.  
4.2.2 Mechanism of Action  
Tipifarnib is a potent and selective inhibitor of farnesyltransferase (FTase), an enzyme 
responsible for adding a farnesyl group to proteins.   
Tipifarnib has consistently shown high activity in HRAS mutated tumor cell lines.  Early 
characterization of tip ifarnib demonstrated that it caused de -farnesylation and loss of membrane 
localization of HRAS, but not KRAS or NRAS ( Lerner 1997 ; Mahgoub 1999 ).  Tipifarnib 
inhibited cell proliferation of HRAS transformed NIH3T3 cells with an IC 50 of 1.7 nM but did 
not inhibit parental NIH3T3 cells up to a concentration of 500 nM ( End 2001 ).  Consistent with a 
specific activity against HRAS, tipifarnib was found to potently inhibit the  only two HRAS 
mutant cell lines from a 53 human tumor cell panel with IC 50 of 1.7 nM and 5.2 nM, whereas cell 
lines with KRAS and NRAS mutations displayed a wide range sensitivity (~ 10 nM to > 500 
nM) ( End 2001 ).   
In preclinic al animal models of HRAS driven cancer, tipifarnib has consistently shown potent 
activity.  In mouse cell line xenograft models, tipifarnib inhibited 86% tumor growth at 25mg/kg 
bid dose in HRAS mutated model while inhibiting only 10% tumor growth at the s ame dose in 
KRAS mutated model ( End 2001 ).  FTIs have also shown strong efficacy in several HRAS 
driven transgenic mouse models ( Kohl 1995 ; Barrington 1998 ; Trempus 2000 ; Chen 2014 ).  
Further, in a methylnitrosourea induced rat mammary tumor model, 90% of tumors with HRAS 
mutation showed complete regression upon tipifarnib treatment, whereas the non -HRAS mutant 
tumors showed variable responses ( Yao 2006 ).  
Tipifarnib has been tested in several clinically relevant  tumor types using patient derived 
xenogra ft (PDX) models. PDX models are thought to be more predictive of clinical activity 
because they are transplanted directly from the patient into host animals without in vitro culture 
and hence retain the properties of the original tumor more faithfully. As shown in  Figure 4 , 
tipifarnib dosed orally at 80mg/kg bid was highly active in PDX models of several HRAS -
mutant HN SCC s inducing tumor stasis, partial responses and some complete regressions of 
established tumors. Importantly, the robust antitumor activity with tipifarnib was achieved in 
models that were resistant to both cetuximab (1mg/kg once weekly, QW) and methotrexate 
(10mg/kg twice weekly, BIW) ( Figure 5 ). 

Tipifarnib   
CTP KO-TIP-007          Page 30  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   Figure 4: Tipifarnib Activity  in HRAS -Mutant HNSCC  PDX Models 
 
 
Figure 5: Tipifarnib Activity  in Cetuximab -Resistant HRAS -Mutant HNSCC  PDX Models  
 
Head and neck tumors with HRAS mutations have previously been reported to be resistant to 
cetuximab and erlotinib in vitro and in vivo ( Rampias 2014 ; Hah 2014 ; Wang 2014 ).  An 
intriguing study recently reported employed serial liquid biopsies from HN SCC  patients to reveal 
that acquired resistance to cetuxim ab in the clinic is in some cases associated with the early 
appearance of de novo  HRAS mutations ( Braig 2016 ).   
4.2.3 Clinical Development  
Several  efficacy  trials  of tipifarnib  in subject s with nonhematological malignancies have bee n 
reported , including those  in subject s with advanced breast cancer, metastatic pancreatic cancer,  
melanoma, small cell lung cancer (SCLC), myelodysplastic syndromes  (MDS) , multiple 
myeloma, urothelial tract transitional cell carcinoma, colorectal cancer and non-small cell lung 
cancer ( NSCLC ) (Adjei 2003 , Cohen 2003 , Johnston 2003 , Alsina 2004 , Heymach  2004 , 
Kurzrock 2004 , Rao 2004 , Rosenberg 2005 , Hong, 2011 , Gajewski 2012 ). While sporadic tumor 
responses were observed in some of these studies, the level of activity in the absence of a 
molecular selection strategy did not support further development of tipifarnib as a single ag ent. 
Preclinical data indicated that tumor models carrying HRAS mutations are highly sensitive to 
FTIs. The reason for this selectivity is potentially the fact that, contrary to KRAS and NRAS, 

Tipifarnib   
CTP KO-TIP-007          Page 31  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   HRAS protein does not undergo geranylge ranylation. Consistent with this hypothesis, Kura  
Oncology initiated  a Phase 2 clinical study in HRAS mutant solid tumors (KO -TIP-001).  
Tipifarnib was  given at a starting dose of 900 mg orally twice daily on days 1 -7 and 15 -21 of 28 -
day cycles.  
 
 
 
 
 
 
 
 
 
 
 
 
 Preliminary data indicate that 5  of 6 evaluable 
HNSCC subjects enrolled in Study KO -TIP-001 have  experienced objective responses (Ho 
2017).  
Tipifarnib was generally well tolerated with hematological events , gastrointestinal disturbances 
(nausea, vomiting and diarrhea) and fatigue constituting the most common adverse events  (AEs) . 
Additional information on KO -TIP-001 is available in the current  version of the Investigator’s 
Brochure.  
4.3 Risk/Benefit s  
Standard therapy for HNSCC is  multimodal consisting of radiation, c hemotherapy and surgery.  
For recurrent and metastatic disease , platinum -based chemotherapy  (cisplatin or carboplatin plus 
5-fluorour acil) with and without  cetuximab , remains an important therapy  (Vermorken 2008 ). 
Other approved systemic therapies  include immunotherapy with pembroluzimab and nivolumab , 
and their use as single agents and in combination in the front -line setting continue to increase  
(KEYNOTE -048; Ferris, 2016 ). Overall response rates to systemic therapy in this indication are 
<20% with a median overall survival of 5 -8 months in the 2 nd line setting ( Seiwert 2016 , Ferris 
2016 ) emphasizing the significant unmet need for effective therapies for the treatment of 
HNSCC.   
HNSCC with HRAS mutations have been shown to be resistant to EGF R inhibition with 
cetuximab and erlotinib in vitro and in vivo ( Rampias 2014 , Hah 2014 , Wang 2014 ).  
Furthermore, a recent study employing serial liquid biopsies from HNSCC patients prior to and 
at progression on cetuximab treatment demonstrated that acquired resistance to cetuximab is 
commonly associated with the early appearance of HRAS mutations ( Braig 2016 ). This last 

Tipifarnib   
CTP KO-TIP-007          Page 32  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   observation also su ggests that additional cases of HRAS -driven HNSCC may arise as a result of 
treatment with anti -EGFR therapy. Additionally, in a comparison of TTP between patients with 
no HRAS mutation (N=48) and HRAS  mutants ( n=7), a statistically significant better progn osis 
for patients with no HRAS mutation (P =0.04)  and a trend toward improved overall survival was 
demonstrated ( Rampias 2014 ).  These published data compliment  preliminary  data from study 
KO-TIP-001 which indicate  that patien ts with HRAS mutant HNSCC may be particular ly 
refractory to multiple standard treatment s of HNSCC .   
Initial data from  the ongoing KO-TIP-001 in which tipifarnib is given at a starting dose of 
600mg (900mg at study start) orally twice daily on days  1-7 and 15 -21 of 28 -day cycles, 
suggests a  tolerability that is broadly similar to the  well characterized safety profile observed in 
prior  clinical studies which administered tipifarnib at dos es up to 600 mg bid daily in a  21-day 
on, 7 days off treatment  cycle schedule.  The most common AE s of tipifarnib including 
hematological events , gastrointestinal disturbances (nausea, vomiting and diarrhea) and fatigue  
are monitorable and manageable with protocol defined assessments and management of toxicity 
guidance .    
Based on the unmet medical need of the HRAS mutant HNSCC population and the favorable 
efficacy and safety results observed in study KO -TIP-001, Kura Oncology has planned KO-TIP-
007 as an international, multicenter, open -label, 2 cohort, non -comparativ e pivotal study 
evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM -HN) and the i mpact of 
HRAS mutations on response to first line systemic  therapies for HNSCC (SEQ -HN).  
4.4 Dose Rationale  
The effect of intermittent schedules of tipifarnib was test ed in several phase 1 studies, including 
a 5-day bid dosing followed by 9 -day rest (5 -day schedule : (Zujewski 2000 ) and two trials 
investigating a 7 -day bid dosing followed by 7 -day rest (7 -day schedule : (Lara 2005 , 
Kirschbaum 2011).  In the 5 -day schedule phase 1 trial in patients with non -hematological 
malignancies, doses from 25 to 1300 mg bid were explored. No MTD was identified. Dose -
limiting t oxicity of grade 3 neuropathy was observed in one patient and grade 2 fatigue in 4 of 6 
patients treated with 1300 mg bid. Fatigue, that was not dose -limiting, was observed at the prior 
dose level (800 mg bid). Of note, myelosuppression which was the most common toxicity in the 
21-day schedule (45% at 300 mg bid, Tipifarnib Investigator’s Brochure 201 8), was limited with 
the 5 -day schedule and included a grade 3 neutropenia in a patient with a prior history of 
myelosuppression treated with 50 mg bid and a g rade 2 thrombocytopenia in a patient treated at 
the 1300 mg bid dose level. No objective responses were noted.  
In the first of the weekly  schedule studies ( Lara 2005 ), the starting dose was 300 mg bid with 
300 mg dose escalation s to a maximum planned dose of 1800 mg bid. Two of 6 patients with 
non-hematological tumors in dose level 3 (900 mg bid) developed grade 3 fatigue attributable to 
study drug, and 600 mg bid on alternate weeks was identified as the recommended phas e 2 dose.  
There were no objective responses but 4 out of 21 patients, 3 of whom had NSCLC, remained on 

Tipifarnib   
CTP KO-TIP-007          Page 33  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   study for at least 1 year with stable disease (12, 13, 16 and 17 months). Five grade 3 events of 
myelosuppression (out of 21 patients) were described by the autho rs (doses not indicated) that 
were not considered dose limiting toxicities ( DLTs ) and hematological toxicity was described as 
moderate and manageable.  
The second weekly  schedule study was conducted in patients with relapsed/refractory AML 
(Kirschbaum 2011 ). Tipifarnib was administered bid on days 1 –7 and days 15 –21 of 28 -day 
cycles at doses up to 1600 mg bid. At the 400 mg bid dose level, a grade 5 hepatorenal failure 
occurred, potentially related to the study drug. There w ere no additional DLTs reported at 600, 
800 or 1000 mg bid dose levels. At the 1200 mg bid dose level, a grade 3 creatinine elevation 
was seen in one patient out of 6 treated. At the 1400 mg bid dose level, one patient experienced a 
grade 4 hypotension and  a rising grade 2 creatinine that were dose limiting, and a second patient 
had a rising grade 2 creatinine that resulted in treatment discontinuation and was therefore 
considered dose limiting. At the 1600 mg dose level, grade 3 liver function tests and a rising 
grade 2 creatinine were dose limiting, and in a second patient, a rapidly rising creatinine was 
seen,  and treatment stopped. As a result, the 1200 mg bid dose was established as the MTD and 7 
additional patients treated. Sixteen patients were treate d at the 1000 and 1200 mg dosing levels, 
with 3 of them experiencing complete responses. No formal responses were seen among patients 
treated at the lower dose levels.  
Based on these data, the tipifarnib regimen investigated in KO-TIP-001, a phase 2  study of 
tipifarnib in nonhematological malignancies that carry HRAS mutations was set with a starting 
dose of 900 mg, orally,  bid on days 1 -7 and 15 -21 of 28 -day treatment cycles.  Preliminary data 
from  KO-TIP-001 indicate  a tolerability that is broadly similar to the safety profile observed of 
other tipifarnib regimens in prior  clinical studies which administered tipifarnib daily in a  21-day 
on, 7 days off treatment  cycle schedule.  The most common AES of tipifarnib including 
hematological events , gastrointestinal disturbances (nausea, vomiting and diarrhea) and fatigue  
have been monitorable and manageable with protocol defined assessments and management of 
toxicity guidance.   Dose r eduction to 600 mg has been able to reduce tipifarnib -related toxicity 
and several subjects have maintained their response and continued on treatment for over 1 year.     
Based on these data, the tipifarnib regimen to be investigated in AIM -HN is a starting  dose of 
600 mg, orally , bid on days 1 -7 and 15 -21 of 28 -day treatment cycles . In the absence of 
unmanageable toxicities, subjects may continue to receive tipifarnib treatment until disease 
progression or unmanageable toxicity . Stepwise 300 mg dose reducti ons to control treatment -
related, treatment -emergent toxicities are further detailed in Section  8.1.2 .  
4.5 Trial Conduct  
This clinical trial will be conducted in compliance with the clinical protocol, current Good 
Clinical Pract ice (ICH Topic E6, GCP) and applicable regulatory requirements.  
Only the Sponsor, upon consultation with the principal Investigator and IDMB may modify the 
protocol. The Sponsor will issue a formal protocol amendment to implement any changes. The 

Tipifarnib   
CTP KO-TIP-007          Page 34  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   only exce ption is when an Investigator considers that a subject’s safety is compromised without 
immediate action. In these circumstances, immediate approval of the chairman of the  
Institutional Review Board/Independent Ethics Committee  (IRB/IEC ) must be sought, and the 
Investigator should inform the Sponsor and the full IRB/IEC within 2 working days after the 
emergency has occurred.  
The IRB/EC must review and approve all protocol amendments. Protocol amendments that have 
an impact on subject risk  or the study objectives or  require revision of the informed consent form  
(ICF), must receive approval from the IRB/IEC prior to their implementation.  
When a protocol amendment substantially alters the study design or the potential risks or burden 
to subje cts, the ICF will be amended and approved by the Sponsor and the IRB/IEC, and all 
active subjects must again provide informed consent.  The approval of the substantial 
amendment from the Competent Regulatory Authority will be sought before implementation.  
4.6 Population  
AIM -HN will enroll at least  80 patients  with head and neck tumors of confirmed squamous 
histology with HRAS muta tions  who have failed prior platinum therapy ( e.g. tumor progression, 
clinical deterioration, or disease recurrence )); however, s ubjects who, at the judgment of the 
investigator, are not considered to be candidates  to receive standard therapy with a platinum -
containing regimen  may be also enrolled.   Platinum based therapy does not have to be the most 
recent prior therapy, however the pa tient must have failed their most recent pr ior therapy. HRAS 
mutations of any variant allele frequency will be enrolled,  
 
Platinum regimens are contraindicated in patients with poor performance status (ECOG  > 3), 
renal dysfunction (creatinine clearance  < 50/mL), otologic disorders, neuropathy > grade 2, 
known hypersensitivity to platinum -based therapy, pregnan t or lactating , or have HIV/AIDS 
(CD4 counts <350/ μL) (Ahn 2016 ). Of note, p oor performance, renal dysfunction, neuropathy, 
pregnancy an d lactation, and lymphopenia can also  be considered potential risk factors for 
tipifarnib th erapy  and therefor e the totality of inclusion/exclusion criteria must be considered 
when determining eligibility. However,  subjects with hearing loss (CTCAE 4.03 hearing 
impaired grade >2), known hypersensitivity to platinum based therapy (prior evidence of a llergic 
reactio n to platinum or mannitol manifested by  skin ra sh, flushing, cardiovascular or respiratory 
symptoms) , or other clinically relevant criteria per investigator judgement that makes  platinum 
based therapy inappropriate for a subject’s treatment  may be enrolled  in KO -TIP-007, without a 
requirement of prior platinum based therapy.  
Additionally, approximately 225 c ontrol patients with HNSCC without detected HRAS 
mutations will be also enrolled as part of  the observational SEQ -HN sub-study , and a su bset of 
those will be matched to the HRAS mutant patients who provide data through pre -screening 
collection, patients enrolled into SEQ without enrolment into AIM -HN, and the AIM -HN study 

Tipifarnib   
CTP KO-TIP-007          Page 35  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   population to the greatest extent possible according to defined pati ent characteristics.  Patients 
will not receive tipifarnib treatment as part of their participation in SEQ -HN.  
5 TRIAL OBJECTIVES  
Primary Objective:   
• To determine the objective response rate (ORR) of tipifarnib in subjects with Head and 
Neck Squamous Cell Carcinoma  (HNSCC) with HRAS mutations with a VAF≥20% 
(High VAF population), as assessed by Independent Review Facility (IRF).   
Key Secondary Objectives:  
• To determine the objective response rate (ORR) of tipifarnib in subjects with Head and 
Neck Squamous Cell Carcinoma  (HNSCC) with HRAS mutations of any VAF (All VAF 
population), as assessed by IRF.  
• To determine the Duration of Response (DOR) of tipifarnib in subjects with Head and 
Neck Squamous Cell Carcinoma  (HNSCC) with HRAS mutations with a VAF≥20% 
(High VAF population), as assessed by IRF.  
• To determine the Duration of Response  (DOR) of tipifarnib in subjects with Head and 
Neck  Squamous Cell C arcinoma  (HNSCC) with HRAS mutations of any VAF (All VAF 
population), as assessed by IRF.  
Other Secondary Objective s for AIM -HN: 
• To determine the anti -tumor activity of tipifarnib in terms of progression free survival, 
and rate of progression free survival  at 6 and 9 months in both the high VAF and all VAF 
populations  
• To determine the anti -tumor activity of tipifarnib in terms of overall survival, and rate of 
overall survival at 12 months in both the high VAF and all VAF populations  
• To determine the anti -tumor activity of tipifarnib in terms of time to response in both the 
high and all VAF populations  
• To determine the anti -tumor activity of tipifarnib in terms of time to progression (TTP) in 
both the high and all VAF populations  
• To investigate the safety a nd tolerability of tipifarnib  according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events v ersion 5.0 (NCI CTCAE 
v5.0) .  
• To investigate the effects of tipifarnib treatment on quality of life measures, including 
EORTC QLQ -H&N35  and EQ -5D-5L. 
• To assess population pharmacokinetics (PK) of tipifarnib in subjects with HNSCC with 
HRAS mutations .   

Tipifarnib   
CTP KO-TIP-007          Page 36  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   6 TRIAL DESIGN  
6.1 Study Endpoints  
Detailed operational definitions of all endpoints are given in  Section 12.1 .  
6.1.1 Primary Endpoint  
The primary endpoint is the proportion of high VAF  subjects with confirmed Objective 
Response (OR), defined as either Complete Response (CR) or Partial Response (PR), calculated 
using the mITT ana lysis set.  
6.1.2 Key Secondary Endpoints  
The key secondary endpoint s include : 
• The proportion of all VAF subjects with confirmed Objective Response (OR), defined as 
either Complete Response (CR) or Partial Response (PR), calculated using the mITT 
analysis set. 
• The duration of response (DOR) in high VAF subjects, calculated using the mITT analysis 
set. 
• The duration of response (DOR) in all VAF subjects, calculated using the mITT analysis 
set. 
 

Tipifarnib   
CTP KO-TIP-007          Page 37  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   6.1.3 Other Secondary Endpoints   
The following are additional secondary  endpoints, evaluated in the AIM -HN part of the study in 
both the high VAF and all VAF populations:  
• Time to response  
• Time to progression (TTP)  
• Progression -free survival (PFS)  
• 6 month and 9 month progression -free survival rate  
• Overall survival (OS)  
• Overall  survival rate at one year  
• Changes in measures of quality of life using the following tools:  EORTC QLQ -H&N35  
and EQ -5D-5L 
• Population PK parameters of tipifarnib  
• Adverse Events  
• Laboratory test results  
• Vital Signs  
• ECG  results  
Response and progression endpoints will be analyzed using both IRF and Investigator 
assessments , as well as using the mITT and per -protocol analysis sets . 
6.2 Study Design  
KO-TIP-007 is an international, multicenter, open -label, pivotal study, with two non -
comparative sub -studies: (1) an interventional open label, single arm, pivotal study evaluating 
the efficacy of tipifarnib in HRAS mutant HNSCC (AIM -HN) and (2) an observa tional study to 

Tipifarnib   
CTP KO-TIP-007          Page 38  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   evaluate the impact of HRAS mutations on response to first line systemic therapies for HNSCC 
(SEQ -HN).  
 AIM -HN, includes HNSCC subjects with HRAS mutations. AIM -HN subjects will receive 
treatment with tipifarnib and the outcome of this sub-study will address the primary objective of 
the KO -TIP-007 study.  SEQ -HN, is an observational sub -study and includes wild type HRAS 
HNSCC subjects who consent to provide first line outcome data and additional follow up. 
HNSCC patients in whom HRAS mutatio ns are identified during SEQ participation, and who 
meet eligibility criteria will be offered participation in AIM -HN.  
 
 
 
 
  
KO-TIP-007 will enroll a total of at least 305 subjects. AIM -HN, the tipifarnib treatment sub-
study of KO -TIP-007, will investigate the effi cacy of tipifarnib in at least 80 subjects with head 
and neck tumors of confirmed squamous histology with HRAS mutations. SEQ -HN, the non -
interventional observational sub-study will enroll an additional, at least 225 subjects with HRAS 
wildtype HNSCC tumor s. Additional HRAS mutant subjects that consent to pre -screening, but 
do not enroll in AIM -HN may have first line treatment data collected as well.  
The study design is shown in Figure 1 . 
6.2.1 AIM -HN Design  
AIM -HN will enroll patients with head and neck tumors of confirmed squamous histology with 
HRAS mutations . Subjects must have failed (e.g.  tumor progression, clinical deterioration, or 
recurrence  their most recent prior therapy, and at least one prior line of systemic platin um-based 
therapy (the most recent prior and platinum -based therapy may be the same regimen). However, 
subjects who, at the judgment of the investigator, are considered not to be candidates to receive 
standard therapy with a platinum -containing regimen may also be enrolled (further detailed in 
Section 4.6 ).  The primary objective of AIM -HN is to determine the ORR of tipifarnib in 
subjects with HNSCC with HRAS mutations and a VAF≥20%, as assessed by IRF.     
To participate in AIM -HN, all subjects must have measurable disease that meets the criteria for 
selection as a target l esion according to Response Evaluation Criteria in Solid Tumors (RECIST) 
v1.1. The presence of at least one measurable target lesion per RECIST v1.1 must be co nfirmed 
by local radiology prior to enrollment. Subjects without at least one measurable target lesion 
confirmed by local radiology will not be enrolled into AIM -HN.  
HNSCC diagnosis by local site pathology laboratory will be used  for study entry ; however,  all 
subjects must provide pathology material for central pathology review.  Confirmation of 
pathological diagnosis of HNSCC will be required for inclusion of subjects in the per -protocol  

Tipifarnib   
CTP KO-TIP-007          Page 39  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   analysis set.  Subjects in whom a diagnosis of HNSCC is not confirme d by central review may 
continue to receive study treatment and will be included in the mITT analysis set.  
All AIM -HN enrolled subjects must have a known missense HRAS tumor mutation based on 
centralized testing or other HRAS test used by the trial site th at has been approved by the 
Sponsor.  HRAS status should be assessed on tumor obtained subsequent to the most recent prior 
therapy in order to obtain the most recent tumor biology; if tumor tissue that does not meet this 
criterion must be used (e.g. risk o f biopsy is too high, patient refuses new biopsy), the 
Investigator  should document the reason. If several samples are available, HRAS testing should 
be performed in the most recently obtained tumor sample.   All subjects must provide enough 
tumor material for confirmation of HRAS status by central lab . This tissue should be from the 
same source as that used for pre -screening, or the reason that is not possible documented.  
Subjects who were enrolled in the study based on HRAS mutation using a Sponsor approved test, 
but in whom a missense HRAS mutation is  not confirmed by central testing, may continue to 
receive study treatment. SEQ -HN subjects who were initially identified as wild type HRAS but 
in whom an HRAS mutation is later detected during the course of their standard therapy, will 
become eligible to enroll in AIM -HN.   
AIM -HN enrolled s ubjects will receive tipifarnib administered at a dose of 600 mg, orally with a 
meal  twice a day (bid) for 7 days in alternating weeks (Days 1 -7 and 15 -21) in 28-day cycles.  
Stepwise 3 00 mg dose reductions to control t reatment -related, treatment -emergent toxicities are 
described in Section 8.1.2 .  In the absence of unmanageable toxicities, subjects may continue to 
receive tipifarnib treatment until  disease progression.  If a complete respon se is observed, and 
subject continues to tolerate therapy,  therapy with tipifarnib will be maintained for at least 6 
months beyond the start of  response.  
Tumor assessment  for the primary analysis will be performed by the IRF according to RECIST 
v1.1 and assessed by an Independent Data Monitoring Board (IDMB).  Investigator assessment 
of tumor response will also be collected and reported  as a supportive analysis . Assessments will 
be performed at screening and approxi mately every 8 weeks for  the first 12 months  of a subject’s 
participation in AIM -HN; thereafter, tumor response assessment should occur  approximately 
every 12 weeks until disease progression .  Radiological assessments will be discontinued at the 
time of tu mor progression.  If the subject initiates a new anticancer therapy without evidence of 
disease progression by RECIST v1.1, tumor scans should continue until there is evidence of 
disease  progression unless withdrawal of subject’s consent to study procedure s.  Local 
investigator evaluation of tumor assessment will guide on -study treatment decisions, including 
decisions to stop study treatment due to progressive disease.   
Upon disease progression, all subjects will be followed approximately every 12 weeks fo r 
survival and the use of subsequent therapy until either death or End of Study (up to 2 years since 
the enrollment of the last study subject in AIM -HN, see Section 6.7.1 ), whichever occurs first.  

Tipifarnib   
CTP KO-TIP-007          Page 40  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   All subjects will be followed -up for safety through  the End of Treatment visit which occurs 
approximately 30 days after treatment discontinuation  or until immediately before the 
administration of another anticancer treatment, whichever occurs first . Additional safety follow -
up may be conducted if unresolved toxicity is present at this End of Treatment visit. The IDMB  
will provide periodic evaluatio ns of safety and other data to ensure adequate benefit/risk  as well 
as the validity and scientific merit of the study.  
An overview of the AIM -HN design is shown in  Figure 2 . 
6.2.2 SEQ -HN Design  
SEQ -HN is an observational sub -study  
  Demographics, 
disease history, information on prior anti -cancer treatments and outcomes to prior treatments for 
HNSCC will be collected from all enrolled subjects. Approximately 225 c ontrol patients with 
HNSCC without known HRAS mutations , will be enrolled into SEQ -HN.  As part of their 
participation in SEQ -HN, patients will be followed up through initiation of second line therap ies. 
At that point, a subset  of the approximate 225 control patients  will be matched to the HRAS 
mutant AIM -HN subjects  to the greatest extent possible according to pre-defined patient 
characteristics. If necessary, additional follow up of the matched HRAS  wildtype HNSCC 
patients enrolled into SEQ -HN may continue until all AIM -HN objectives are completed and 
KO-TIP-007 end of study is reached. Control patients with HNSCC with wildtype HRAS  will 
not receive tipifarnib treatment as part of their participatio n in SEQ -HN; however, they  may be 
compensated for their participation in data collection, blood sampling, screening and follow up 
procedures according to institutional guidelines.  
An overview of the SEQ -HN design is shown in  Figure 3 . 
6.3 Randomization  
KO-TIP-007 is a nonrandomized study. S ubjects enrolled as part of AIM -HN will receive 
tipifarnib administered at a dose of 600 mg, orally with food, bid for 7 days in alternating weeks 
(Days 1 -7 and 15 -21) in 28-day cycles.   
SEQ -HN is noninterventional and used for data collection in subjects with HNSCC without 
HRAS mutations .  Subjects enrolled in SEQ -HN will not receive tipifarnib treatment.  
This is an open label study with no placebo or comparators.  
6.4 Maintenance  
No randomization c ode will be used for this nonrandomized, open label study.  

Tipifarnib   
CTP KO-TIP-007          Page 41  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   6.5 Trial Treatment  
Subjects enrolled as part of AIM -HN will receive tipifarnib  as monotherapy in this study. 
Subjects may continue to receive tipifarnib therapy i n the absence of unacceptable  tipifarn ib 
related emergent toxicity or disease progression . Kura  Oncology , Inc. or  its designee will provide 
the study site with a supply of tipifarnib  sufficient for the completion of the study.  
All study subject s will be also eligible to receive best supportive care (BSC) defined as any 
standard supportive measure s that are  not considered a primary treatment of the disease under 
study .  Supportive measures may include, for example, the use of growth factors (i.e. granulocyte 
colony stimulating factor, GCSF) or blood transfusions . BSC will be provided by the study sites.  
Subjects with HNSCC without HRAS mutations will not receive tipifarnib treatment as part of 
their participation in SEQ -HN and may continue to receive other anticancer therapies and care 
for their disease according to institutional practice.  
The following sub -sections apply only to subjects enrolled as part of AIM -HN. 
6.5.1 Investigational Product (IP)  
Tipifarnib  is a small molecule being developed as a potent,  selective inhibitor of FTase for t he 
treatment of HRAS mutant HNSCC and other malignancies . Tipifarnib  will be administered  at a 
starting dose of 600 mg, orally , bid on days 1 -7 and 15 -21 of 28 -day treatment cycles .  
6.5.2 Product Characteristics  
Tipifarnib film -coated tablets for oral administration are supplied in high density polyethylene 
(HDPE ) bottles. Two strengths (100 mg and 300 mg) of tablets are provided containing either 
100 mg or 300 mg of tipifarnib active substance, respectively. In a ddition to the active substance, 
the tablets contain the following inactive ingredients: lactose monohydrate, maize starch, 
hypromellose, microcrystalline cellulose, crospovidone, colloidal anhydrous silica, and 
magnesium stearate. The nonfunctional, taste -masking film coatings contain hypromellose, 
titanium dioxide, lactose monohydrate, polyethylene glycol, and triacetin. Each strength of tablet 
contains the same quantitative composition of the same excipients. Further information can be 
obtained from the current version of the Tipifarnib Investigator’s Brochure.  
6.5.3 Storage and Labeling  
Tipifarnib  should be stored at controlled room temperature 15 to 30 C (59 to 86 F). All study 
supplies must be kept in a restricted access area.  
At a minimum, the label of each bottle  of tipifarnib tablets shipped to the study sites will provide 
the following information: batch number/lot number, study identification, required storage 
conditions , directions for use, and country  specific required caution statements ( e.g. in the US, 
“New Drug – Limited by United States federal law to investigational use ”). 

Tipifarnib   
CTP KO-TIP-007          Page 42  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   Tipifarnib  accountability records will be maintained by the pharmacy or designated drug 
preparation area at the study site s. Upon receipt of tipifarnib  supplies, the pharmacist or 
designated study site investigational drug handler will inventory tipifa rnib (separately for each 
strength , if applicable ) and complete the designated section of the shipping form. The 
shipping/inventory form must be sent to Kura  Oncology , Inc.  or its designee, as instructed.  
6.5.4 Emergency Medical Support and Subject Card  
Subjects  enrolled in this clinical study  will be provided with Emergency Medical Support cards  
during their study  partic ipation, which will be provided  by the Sponsor  or designee . The 
Emergency Medical  Support card provides clinical study  subjects with a way of id entifying  
themselves as participating in a clinical study  and subsequently to give health care providers  
access to the information about this participation that may be needed to determine the course of  
the subject’s medical treatment.  
This service is desig ned to provide information to health care providers who are not part of the  
clinical study . Clinical study I nvestigators, who are already aware of the clinical study  protocol 
and treatment,  have other means of accessing the necessary medical information fo r the 
management of  emergencies occurring in their subjects.  
The first point of contact for all emergencies will be the clinical study  Investigator caring for the  
affected subject. The Investigator agrees to provide his or her emergency contact information  on 
the card for this purpose. If the Investigator is available when an event occurs, s/he will answer  
any questions. Any subsequent action will follow the standard processes established for the  
Investigators.  
In cases where the Inves tigator is not availab le, the Sponsor or designee will provide a 24 hour 
contact number whereby  health care providers will be given access to the appropriate Sponsor ’s 
physician or designee to assist with any  information regarding tipifarnib in case of a medical 
emergency.  
6.6 Duration  
Subjects enrolled as part of AIM -HN may receive treatment with tipifarnib until disease 
progression , unacce ptable toxicity  or any criteria for withdrawal from the trial or treatment 
occurs (see  Section 7.3 ). Kura  Oncology , Inc. or  its designee will provide the study site with a 
supply of tipifarnib  sufficient for the completion of the study.  Upon disease progression, all 
subjects will be followed approxima tely every 12 weeks for survival and the use of subsequent 
therapy  until either death or End of Study (see Section 6.7.1 ), whichever occurs first.  
Subjects enrolled into  SEQ -HN will be followed through initiation of second li ne therapy, death, 
or consent withdraw, whichever occurs first. Additional follow up of the matched HRAS 
wildtype HNSCC patients enrolled into SEQ -HN may continue until all AIM -HN objectives are 
completed and End of Study  (see Section 6.7.1 ) is reached . 

Tipifarnib   
CTP KO-TIP-007          Page 43  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   6.7 Discontinuation  
6.7.1 Definition of End of Study  
For administrative and safety reporting  purposes, the end of this clinical study is defined as 2 
years  from enrollment of the last enrolled study subject  in AIM-HN.  If the last enrolled study 
subject discontinues treatment within 2 years  of study enrollment, the End of Study will occur no 
earlier than the date of the last enrolled subject’s safety follow -up assessment  (End of Treatment 
visit)  performed approxi mately 30 days after treatment discontinuation or until initiation of 
another anti -cancer therapy , whichever occurs first .  At the time of End of Study, provisions will 
be made to transition all remaining AIM -HN subjects who demonstrate sustained clinical benefit 
beyond the end of the study to other means of continued treatment with tipifarnib  with 
appropriate safety monitoring , e.g. single patient treatment protocol , other clinical trial or 
expanded access protocol , as allowed by local law .   
6.7.2 Premature Dis continuation of the Trial  
This trial may be discontinued prematurely in the event of any of the following:  
• IDMB recommendation based on observed safety leading to an unfavorable risk -benefit 
of tipifarnib.  
• IDMB recommendation based on futility criteria.  
• New information leading to a judgment of unfavorable risk -benefit of tipifarnib becomes 
available, e.g. due to evidence of inefficacy of tipifarnib in HRAS mutant tumors, 
occurrence of significant previously unknown adverse reactions or unexpectedly high 
intensity or incidence of previously known adverse reactions, or other unfavorable safety 
findings in the HRAS mutant tumor subject population. Evidence of inefficacy may arise 
from this trial or from other trials and unfavorable safety f indings may arise from clinical 
or non -clinical examinations, e.g. toxicology.  
• Sponsor’s decision that continuation of the trial is unjus tifiable for medical or ethical 
reasons.  
• Poor enrollment of subjects making completion of the trial within an acceptabl e time 
frame  unlikely.  
• Discontinuation of development of tipifarnib by the Sponsor .  
• Request by a Health Authority . 
Health Authorities and IRBs/IECs will be informed about the discontinuation of the trial in 
accordance with applicable regulations. In the case of premature discontinuation of the study, the 
investigations scheduled for the End of Treatment visit should be performed and the appropriate 
electronic case report form (eCRF) section completed.  

Tipifarnib   
CTP KO-TIP-007          Page 44  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   6.8 Product Accountability  
The Investigator  or designee is  responsible for maintaining accurate records (including dates and 
quantities) of IP received, subjects t o whom IP is dispensed (subject by subject specific 
accounting), and IP lost or accidentally or deliberately destroyed.  
Unused tablets returned by the  subject from a prior cycle of treatment may be re -dispensed to the 
subject.  
Study drug must be kept in a secure location for accountability and reconciliation by the 
Sponsor’s  designated clinical trial monitor . The Investigator or designee must provide a n 
explanation for any destroyed or missing study drug or study materials.  
Study drug may be destroyed on site, per the site’s standard operating procedures, but only after 
the Sponsor or its designee has been notified and granted approval for drug destruct ion. All study 
drug destroyed on site must be documented. If a site is unable to destroy study drug 
appropriately, the site can return unused study drug to the Sponsor  or its designee upon request. 
The return of study drug or study drug materials  must be a ccounted for on a f orm provided by 
the Sponsor  or its  designee.  
Documentation must be provided to the Sponsor or its  designee and retained in the Investigator ’s 
study files.  
All study drug and related materials should be stored, inventoried, reconciled and  destroyed  or 
returned according to applicable state and federal regulations and study procedures.  
6.9 Data Identification  
6.9.1 Subject Identification and Privacy  
Kura Oncology, Inc. or its designee will assign a subject number identifier for each subject that 
is enrolled into the study  upon completion of informed consent for prescreening for HRAS 
mutations . This unique identifier will be on all  eCRF pages  and will serve as the subject’s 
identifier in the study as well as in the clinical study  database.  
The subject ’s data collected in the study  will be stored under this number. Only the Investigator  
will be able to link the subject’s study  data to the subject via an identification list kept at the site.  
The subject’s original medical data that are reviewed at the si te during source data verification  
by the Monitor, audits and Health Authority inspections will be kept strictly confidential.  
Data protection and privacy regulations will be observed in capturing, forwarding, processing  
and storing subject data. Subjects will be informed accordingly and will be requested to give  
their consent on data handling procedures in accordance with national regulations.  

Tipifarnib   
CTP KO-TIP-007          Page 45  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   6.9.2 Case Report Form Management  
The Investigator or designee will be responsible f or entering study data in the e CRFs that will be 
provided by  the Sponsor  or its designee . It is the Investigator’s responsibility to ensure the 
accuracy of the data entered in  the eCRFs.  Database lock will occu r once quality control  and 
quality assurance  procedures (if applicable) have been completed.  
6.9.3 Source Data and Subject Files  
The Investigator must keep a subject file (medical file, original medical records) on paper or  
electronically for every subject included in the study . This file will contain the available  
demographic and medical in formation for the subject and should be as complete as possible.  
In particular, the following data should be available in this file:  
• Subject’s full name  
• Date of birth  
• Gender  
• Height  
• Weight  
• Relevant m edical history and concomitant diseases  
• Prior and concomitant therapies (including changes during the study ) 
• Study identification  
• Date of subject’s inclusion int o the study (i.e. date of  informed consent)  
• Subject identifier  in the study  
• Dates of the subject’s visits to the site  
• Any medical examinations and clinical findings predefined  in the clinical study protocol  
• All AEs observed in the subject  
• Date of subject’s end of study , and  
• Date of and reason for early withdrawal of the subject from the study  or from treatment , 
if applicable.  
It must be possible to identify each subject by using this subject file.  Additionally, any other 
documents containing source data must be filed. This includes original  printouts of data recorded 
or generated by automated instruments, CT scan images, ECG  recordings, laboratory value 
listings, etc. Such documents must bear at least the subject identifier and the date when the 
procedure was performed. Information should be printed by the instrument  used to perform the 
assessment or measurement, if possible. I nformation that cannot be printed  by an automated 

Tipifarnib   
CTP KO-TIP-007          Page 46  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   instrument will be entered manually. Medical evaluation of such records should  be documented 
as necessary and the documentation signed and dated by the Investigator.  
The following  information described in t he eCRFs is regarded as the source data:  
• Any Investigator ’s comments  
• Subject identifier  
• Information on AE (e.g. seriousness, severity, outcome, and causality to the IP)  
• Reason for providing concomitant medications and procedures (if applicable)  
• Assessment of antitumor effect including tumor measurements  
• Description about study discontinuation  
7 SELECTION  AND WITHDRAWAL OF SUBJECTS  
7.1 Inclusion Criteria   
7.1.1 Inclusion Criteria: AIM -HN 
For inclusion of a subject in the tipifarnib treatment portion of the study  (AIM -HN), all of the 
following inclusion criteria must be fulfilled . If a subject does initially not meet any inclusion 
criteria, the subject may be re -screened at a later time :  
1. At least 18 years of age . 
2. Histologi cally confirmed head and neck cancer (oral cavity, pharynx, larynx, sinonasal, 
nasopharyngeal, or unknown primary) of squamous histology not amenable to local therapy 
with curative intent (surgery or radiation therapy with or without chemotherapy). Enrol lment 
may proceed with local diagnosis but all subjects must consent to provide tumor tissue for a 
central pathology review.  
3. Documented treatment failure from most recent prior therapy (e.g. tumor progression, 
clinical deterioration, or recurrence), and from  at least one prior platinum -containing 
regimen, in any treatment setting . The most recent prior and platinum -based therapy may be 
the same regimen. Those subjects who, at the judgment of the investigator, are considered 
clinically unsuitable to receive st andard platinum -containing regimen, may also be enrolled 
and the reason for clinical unsuitability recorded.  There is no limit on the number of prior 
lines of therapy.  
4. Known tumor missense HRAS mutation detected by Next Generation Sequencing (NGS) or 
any other methodology approved by the Sponsor.  Variant allele frequency (VAF) needs to 
be determined and must be available.  HRAS status should be assessed on tumor tissue 
obtained subsequent to the most recent prior therapy so that the most accurate tumor bio logy 
is evaluated.  I f tumor tissue that does not meet this criterion must be used (e.g. risk of new 

Tipifarnib   
CTP KO-TIP-007          Page 47  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   biopsy is too high, patient refuses new biopsy), the investigator should document the reason. 
Enrollment may proceed with the identification of a missense HRAS mutation using a test 
preferred by the investigator  and approved by the Sponsor  during pre -screening , but all 
subjects must consent to provide tumor tissue for central HRAS confirmation .  
 
 
5. Measurable disease by RECIST v1.1 (Appendix I) that meets the criteria for selection as a 
target lesion according to RECIST v1.1.  The presence of at  least one measurable target 
lesion per RECIST v1.1 must be confirmed by local radiology prior to subject entry.  
6. At least 2 weeks or 5 half-lives, whichever is longer, since the last systemic therapy regimen 
prior to Cycle 1 Day 1. Last dose of any prior c heckpoint inhibitor therapy must have been 
administered at least 2 weeks prior to C1D1 . Subjects must have recovered to NCI CTCAE 
v5.0 < Grade 2 from all acute toxicities (excluding Grade 2 toxicities that are not considered 
a safety risk by the Sponsor an d Investigator) or toxicity must be deemed irreversible by the 
Investigator.  
7. At least 2 weeks since last radiotherapy. Subjects must have recovered from all acute  
toxicities from radiotherapy.  
8. ECOG performance status of 0 -1 (Appendix II ). 
9. Acceptable liver function:  
a) Bilirubin  1.5 times upper limit of normal (x ULN) . 
b) AST (SGOT) and ALT (SGPT)  1.5 x ULN . 
The subject must meet/continue to meet these criteria at the time of first dosing, as 
confirmed by analysis within 72 hours of C1D1.  
10. Acceptable renal function with either serum creatinine  1.5 x ULN  or a calculated creatinine 
clearance ≥ 60 mL/min using the Cockcroft -Gault or Modification of Diet in Renal Disease 
(MDRD ) formulas.  
The subject must meet/continue to meet th ese criteria at the time of first dosing, as 
confirmed by review of analysis performed within 72 hours of C1D1.  
11. Acceptable hematologic status:  
a) ANC  1000 cells/μL.  
b) Platelet count  75,000/μL.  
c) Hemoglobin  8.0 g/dL.  
The subject must meet/continue to meet these criteria at the time of first dosing, as 
confirmed by review of analysis performed within 72 hours of C1D1.  

Tipifarnib   
CTP KO-TIP-007          Page 48  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   12. Female subjects must be:  
a) Of non -child -bearing potential (surgically sterilized or at least 2 years post -
menopausal); or  
b) If of child -bearing potential, subject must use a highly effective method of 
contraception, such as combined (estrogen and progestogen containing) hormonal 
contraception associated with inhibition of ovulation, progestogen -only hormonal 
contraception asso ciated with inhibition of ovulation, intrauterine device, 
intrauterine hormone -releasing system, bilateral tubal occlusion, vasectomised 
partner or sexual abstinence.  Both females and male subjects with female 
partners of child -bearing potential must agre e to use a highly effective method of 
contraception from the first dose of tipifarnib , during  tipifarnib treatment , and at 
least 28 days after last dose of  tipifarnib  for females and 90 days for males. 
Female subjects must have a negative serum or urine pr egnancy test within 72 
hours prior to start of trial medication.  
c) Not breast feeding at any time during the study.  
13. Written and voluntary informed consent understood, signed and dated . 
7.1.2 Inclusion Criteria: SEQ -HN 
For inclusion of a subject in the nonintervent ional portion of the study  (SEQ -HN), all of the 
following inclusion criteria must be fulfilled:   
1. At least 18 years of age . 
2. Histologically confirmed head and neck cancer (oral cavity, pharynx, larynx, sinonasal, 
nasopharyngeal, or unknown primary) of squamous histology .   
3. HRAS wildtype (i.e. have no identified  tumor missense HRAS mutation ) determined by a 
test preferred by the investigator  and approved by the Sponsor or through central HRAS 
testing.   
4. Will or has received at least one systemic anti -cancer therapy for recurrent or metastatic 
HNSCC for which there is availabl e outcome information in terms of ORR, or can be 
determined based on the subject’s records. Subjects  who have not yet received or completed 
at least one systemic anti -cancer therapy fo r recurrent or metastatic HNSCC must consent to 
the collection of treatment outcome information and additional fol low up contact  in order to 
participate in the SEQ -HN portion of the study.  
5. Written and voluntary informed consent understood, signed and date d. 

Tipifarnib   
CTP KO-TIP-007          Page 49  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   7.2 Exclusion Criteria  
7.2.1 Exclusion Criteria : AIM -HN 
If a subject initially meets any exclusion criteria, the subject may be re -screened at a later time.  
1. Has disease that is suitable for local therapy administered with curative intent . 
2. Histologically confirmed salivary gland , thyroid, (primary) cutaneous squamous  or 
nonsquamous histologies (e .g. mucosal melanoma) .  
3. Known additional malignancy that is progressi ng or requires active treatment  (excluding 
non-melanoma skin cancer, adjuvant h ormonal therapy for breast cancer and hormonal 
treatment for castration sensitive prostate cancer).  
4. Ongoing treatment with an anticancer agent not contemplated in this protocol  (excluding 
adjuvant hormonal therapy for breast cancer and hormonal treatment f or castration sensitive 
prostate cancer) . 
5. Prior treatment (at least 1 full treatment cycle)  with a  farnesyltransferase inhibitor  (FTI) . 
6. Any use of investigational therapy within 2  weeks of Cycle 1 Day 1 (C1D1) or 5 half -lives 
(whichever is longer ). Last do se of any prior checkpoint inhibitor therapy must have been 
administered at least 2 weeks prior to C1D1.  
7. Received treatment for unstable angina within prior year, myocardial infarction within the 
prior year, cerebro -vascular attack within the prior year, history of New York Heart 
Association grade III or greater congestive heart failure, or current serious cardiac arrhythmia 
requiring medication except atrial fibrillation.  
8. Non-tolerable  Grade 2 or ≥  Grade 3 neuropathy or evidence of unstable neurolog ical 
symptoms within 4 weeks of Cycle 1 Day 1. Non -tolerable Grade 2 toxicities are defined as 
those with moderate symptoms that the subject is not able to endure for the conduct of 
instrumental activities of daily life or that persists ≥ 7 days.  
9. Major sur gery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without 
complete recovery.  
10. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy , 
including  known history of infection with human immunodeficiency virus  or an active 
infection with hepatitis B or hepatitis C.  
11. Subjects who have exhibited allergic reactions to tipifarnib or structural compounds similar 
to tipifarnib or to its excipients. This includes hypersensitivity to imidazoles, such as 
clotrimazol e, ketoconazole, miconazole and others in this drug class. Subjects  with 
hypersensitivity to these agents will be excluded from enrol lment.  
12. Required use of concomitant medications classified as s trong inhibitors or inducers of 
cytochrome P450 3A4 ( CYP3A4 , Table 1 1) or UDP -glucuronosyltransferase (UGT).    

Tipifarnib   
CTP KO-TIP-007          Page 50  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   13. Concomitant disease or condition that could interfere with the conduct of the study or that 
would, in the opinion of the investigator, pose an unacceptable risk to the subject in this 
study.  
14. Female subjects who are pregnant or lactating.  
15. Unwillingness or inability to comply with the study protocol for any reason.  
7.2.2 Exclusion Criteria: SEQ -HN 
A subject may not be enrolled in the  noninterventional portion  of the study  (SEQ -HN), if any  of 
the following exclusion  criteria  apply :  
1. Histologically confirmed salivary gland , thyroid, (primary) cutaneous squamous  or 
nonsquamous histologies (e .g. mucosal melanoma) .  
2. Concomitant disease or condition that could interfere with the  conduct of the study or that 
would, in the opinion of the investigator, pose an unacceptable risk to the subject in this 
study.  
3. The subject has legal incapacity or limited legal capacity.  
7.3 Subject Withdrawal  
7.3.1 Removal of Subjects from Treatment or Assessmen t 
Subjects may withdraw their consent to participate in this study at any time without prejudice. 
The Investigator must withdraw from the study any subject who requests to be withdrawn. A 
subject’s participation in the study may also be discontinued at any t ime at the discretion of the 
Investigator and in accordance with his/her clinical judgment. Every effort should be made to 
complete, whenever possible, the tests and evaluations listed for the End of Treatment visit in 
AIM -HN subjects . The Sponsor  must be notified of all subject withdrawals as soon as possible. 
The Sponsor  also reserves the right to discontinue the study at any time for either clinical  
research  or administrative reasons and to discontinue participation by an individual Investigator 
or site for poor enrollment or noncompliance.  
Overall, the r easons for which the Investigator or Kura  Oncology may withdraw a subject from 
study treatment include, but are not limited to, the following:  
• Subject experiences disease progression  
• Subject experiences unacceptable toxicity  
• Subject experie nces toxicity that is deemed  by the Investigator to be no longer safe for 
the subject to continue therapy  
• Subject requests to withdraw from the study treatment  
• Subject requires medication prohibited by the p rotocol  

Tipifarnib   
CTP KO-TIP-007          Page 51  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   • Subject is unwilling or unable to comply with the study requirements  
• Subject withdraws consent to collect health information  
• Subject was erroneously admitted into the study or does not meet entry criteria  
• Subject is lost to follow -up 
• Subject become s pregnant  
Subjects enrolled in AIM -HN will return for an End of Treatment visit within approximately 30 
days after the last administration of the study drug  (or sooner if another anticancer therapy is to 
be initiated) . If a subject fails to return for sch eduled visits, a documented effort must be made to 
determine the reason. If the subject cannot be reached by telephone after 2 attempts, a certified 
letter should be sent to the subject (or the subject’s legally authorized representative,  if 
appropriate) r equesting contact with the Investigator. This information should be recorded in th e 
study records.  
Prior to enroll ment into the study, the Investigator or designee must explain to each subject, that 
the subject’s protected health information obtained duri ng the study may be shared with the 
study Sponsor, regulatory agencies, and IRB/IEC in order to analyze and evaluate study results. 
It is the Investigator’s (or designee’s) responsibility to obtain written permission to use protected 
health information per  country -specific regulations, such as Health Insurance Portability and 
Accountability Act (HIPAA) in the  United States ( US), from each subject, or if appropriate, the 
subject’s legally authorized representative. If permission to use protected health infor mation is 
withdrawn, it is the Investigator’s responsibility to obtain a written request, to ensure that no 
further data will be collected from the subject and the subject will be removed from the study.  
7.3.2 Medical Care of Subjects after End of Trial  
After a subject has completed the trial or has withdrawn from the study, standard  treatment will 
be administered, if required, in accordance with the trial site’s standard of care and generally 
accepted medical practice and according to  the subject’s indiv idual medical needs.  
7.3.3 Replacement of Subjects  
Subject with HRAS mutant HNSCC who are enrolled in KO -TIP-007 and receive a dose of 
tipifarnib (mITT population for the primary objective) will not be replaced.  
SEQ -HN Subjects (HNSCC without HRAS mutations) who  are enrolled as part of SEQ -HN and 
found t o have an HRAS mutation following enrollment will be offered participation in AIM -HN 
(assuming all other eligibility criteria are met).  These subjects may be replaced.  SEQ -HN 
subjects (HNSCC without known HRAS mu tations) who are enrolled and discontinue 
participation prior to the collection of outcome data on first line systemic treatment for recurrent 
or metastatic HNSCC (dates of treatment, performance status, treatment outcome and date of 
progression) may be re placed.  

Tipifarnib   
CTP KO-TIP-007          Page 52  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   8 TREATMENT OF SUBJECTS  
KO-TIP-007 is a nonrandomized study. S ubjects enrolled as part of AIM -HN will receive 
tipifarnib treatment .   
SEQ -HN is noninterventional and used for data collection in control subjects with HNSCC 
without HRAS mutations.  Sub jects enrolled in SEQ -HN will not receive tipifarnib treatment  and 
may continue to receive other anticancer therapies and care for their disease according to 
institutional practice . 
The following sub -sections apply only to subjects participating in AIM -HN, the tipifarnib 
treatment portion of KO -TIP-007. 
8.1 Medication  
8.1.1 Tipifarnib Administration  
Tipifarnib  will be administered  with food at a starting dose of 600 mg, orally , bid on days 1 -7 
and 15 -21 of 28 -day treatment cycles .  
Tipifarnib  should  be administered orally with a meal , and again with a meal approximately 12 
hours later  at approximately the same times each treatment day. The interval between 
administrations should be not less than 8 hours.  Subjects should be instructed on the importan ce 
of taking their tipifarnib dose with a meal as the presence of food has been shown to improve the 
absorption of tipifarnib, as well as to reduce variability in the pharmacokinetic profile.   
Tablets should be swallowed whole with water (~8 oz.  or 250 mL ). Tablets may be chewed or 
crushed if the Investigator deems it necessary . Use of a p ercutane ous endoscopic gastrostomy  
tube or nasogastric tube is allowed at the judgment of the Investigator.  
If a dose is vomited or partially vomited it should not be re placed  with a new dose.  Dosing 
should resume at the next scheduled dose time.  
The first study dosing (Cycle 1 Day 1) will take place in the study clinic. On Cycle 1 Day 1 , the 
investigator  will provide  tipifarnib  to the subj ect from bulk supplies . Subjects will be provided 
with diaries with instructions to record the date and time of each dose and ask ed to bring the 
diaries and tablet  bottles to each clinic visit for subject  compliance and drug accountability 
review by the  site staff.   

Tipifarnib   
CTP KO-TIP-007          Page 53  
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   

Tipifarnib   
CTP KO-TIP-007          Page 54  
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   

Tipifarnib   
CTP KO-TIP-007          Page 55  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   

Tipifarnib   
CTP KO-TIP-007          Page 56  
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   

Tipifarnib   
CTP KO-TIP-007          Page 57  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   8.1.3 Treatment of Tipifarnib Overdose  
An overdose is defined as any dose greater than  20% over  the daily  intended tipifarnib  dose. Any 
overdose must be recorded in the trial medication and AE section s of the eCRF. There is no 
known antidote for tipifarnib . In the event of overdose of tipifarnib , subjects should receive 
appropriate advice and supportive medical care by the Investigat or or his/her designee  and be 
followed -up accordingly . 
For monitoring purposes, any case of overdose – whether or not associated with an AE (serious 
or non -serious) – must be reported to the Spo nsor in an expedited manner . 
8.1.4 Prior and Concomitant Medications  
All prescription and over -the-counter medications taken by a subject within 28 days before the 
first study drug administration will be recorded in the eCRF.   In particular, subjects will be asked 
about the use of agents that may affect the mevalonate path way including statins (e.g. 
atorvastatin, rosuvastatin, pravastatin), bisphosphonates (e.g. pamidronate, risedronate, 
ibandronate, etidronate, alendronate) and nutritional agents (e.g. coenzyme Q ₁₀, ubiquinone).  
Supportive care medications , e.g. transfusions , growth factors  or intravenous hydration, 
considered necessary for the subject’s safety and well -being may be given at the discretion of the 
Investigator. Any additional concomitant therapy that becomes necessary during the trial and an y 

Tipifarnib   
CTP KO-TIP-007          Page 58  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   chang e to concomitant drugs must be recorded in the corresponding sectio n of the eCRF, noting 
the name, dose, duration,  and indication of each drug.  
BSC will be provided by the clinical study sites according to local guidelines and standard 
practices.  
Furthermo re, the following treatments are allowed during the trial:  
• Correction of electrolyte deficiency.  
• Radiothera py for pain control against non -target lesions as long as it  is not anticipated to 
influence bone marrow function.  
• Total tumor resection in responding subjects who have become candidates for curative 
resection.  
• Hematopoietic growth factors and transfusions of blood or blood products  in subjects 
who are experiencing  hematological toxicity in accordance with standard institutional 
practice.  However, such supportive care should not be used prior to hematological 
findings  unless absolutely clinically necessary and after discussion with the Sponsor or 
designee’s medical monitor.  
• Antiemetic therapy in a subject experiencing gastrointestinal symptoms in accordance 
with standard clinical practice.  If a subject experiences vo miting or nausea, prophylactic 
antiemetic medications may be administered with subsequent treatment in accordance  
with standard clinical practice.  
• Concurrent use of adjuvant hormonal therapy for breast cancer or hormonal treatment for 
castr ation sensitive prostate cancer .  
8.1.5 Non-permitted Treatments  
Use of the followi ng medications and therapies is  not allowed during the trial  in subjects 
participating in AIM -HN: 
• Investigational agents other than tipifarnib . 
• Any other anticancer therapy, including radiation or surgery, for the primary disease 
under study  with the exception of palliative treatment of non -target lesions or treatmen t 
of residual disease in study subject s who have experienced a partial response  during the 
study .  
• High dose systemic cort icosteroids or any other i mmunosuppressive drugs except : 
o Systemic glucocorticosteroid treatment administered with a  daily dose of ≤ 20  mg 
predniso ne or equivalent,  
o Single doses for the management of treatment -related AEs or for premedication  of 
BSC agents . 

Tipifarnib   
CTP KO-TIP-007          Page 59  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   o Short course (≤ 7 days , including tapering ) high dose systemic steroids for the 
treatment of upper airway obstruction associated with HNSCC  
• Strong inhibitors or inducers of CYP3A4 or UGT beginning at least 14 day s prior to 
Cycle 1 Day 1 and  during  the subject’s participation in the tipifarnib treatment portion of  
this study .  See Appendix III  (Table 12) for a list of medications classified as strong 
inhibitors or inducers of CYP3A4.   If continued concomitant therapy is needed, subjects 
should be transitioned to a medicine that is not a s trong inhibitor or inducer of CYP3A4 
or UGT.  
• Sensitive substrates of CYP3A4 beginning Cycle 1 Day 1 and during  the subject’s 
participation in the tipifarnib treatment portion of this study .  See Appendix III  (Table 12) 
for a list of medications classified as sensitive CYP3A4 substrates.  If continued 
concomitant therapy is needed, subjects s hould be transitioned to a medicine that is not a 
sensitive substrate  of CYP3A4 . 
• Enzyme -inducing anti -convulsants (e.g.  phenytoin, phenobarbital, and carbamazepine) 
beginning at Cycle 1 Day 1 and during  the subject’s participation in the tipifarnib 
treatment portion of this study .  If needed, s ubjects may use non -enzyme -inducing anti -
convulsants (e.g.  gabapentin, topiramate, valproate) while taking tipifarnib.  
If the administration of a non -permitted co ncomitant drug becomes necessary during the trial,  
e.g., because of AEs or disease progression, the subject in question will be withdrawn from the 
trial, and the subject’s data which will have been obtained before  the withdrawal may be used for 
safety and efficacy evaluations.  
8.1.6 Dietary or Other Protocol Restrictions  
No dietary restrictions  related to tipifarnib  are required .  Subjects will be instructed to administer 
their dose of tipifarnib  with a meal as the presence of food has been shown to improve the 
absorption of tipifarnib, as well as to reduce variability in the pharmacokinetic profile.   
Tablets should be swallowed whole with water (~8 oz.  or 250 mL). Tablets may be chewed or 
crushed  if the Investigator deems it necessary . Use of a p ercutane ous endoscopic gastrostomy  
tube or nasogastric tube is allowed at the judgment of the Investigator.  
Unless otherwise contraindicated, subjects should be advised to be appropriately hydrated during  
the course of the study (e.g. drinking at least 8 glasses of water/day).  
8.1.6.1  Potential Effects on Reproduction and Development  
Male and female fertility and reproductive capacity has been shown to be impaired in rat s and 
additional details can be found in the Tipifarnib Investigator ’s Brochure.   
In light of the  observations  in nonclinical testing , both female subjects and male subjects with 
female partners of child -bearing potential must agree to use a highly effecti ve method of 

Tipifarnib   
CTP KO-TIP-007          Page 60  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   contraception from the first dose of tipifarnib , during, and at least 4 weeks after last dose of trial 
medication.  Female subjects of child -bearing potential must have a negative serum or urine 
pregnancy test within 72 hours prior to start of  trial medication.  
Additionally, since tipifarnib could induce toxicity of male reproductive organs and cause 
impairment of fertility, sperm cryopreservation should be recommended for male subjects 
wishing to preserve their fertility following tipifarnib t reatment.  Additionally, if the participant in 
the study is male, then the following items will be discussed with the subject:  
• Prevention of pregnancy in a female partner  
• Prevention of exposure of a partner to semen by any means (not just intercourse)  
• Preve ntion of the possible exposure of a pregnant female to the study drug from semen.  
• Informing their partner of the potential for harm to an unborn baby. The partner should 
know that if pregnancy occurs, she should promptly notify her personal doctor.  
• Accepta ble methods of birth control for male subjects while participating in this study 
and for 90 days  after the last dose of the study drug:  
o Abstinence (no sex)  
o Condom plus spermicidal agent (foam gel/cream/film/suppository)  
8.2 Monitoring of Subject Compliance  
The importance of treatment compliance should be emphasized to the subject. Subjects will be 
given study drug and detailed instructions on how to take medications at home. Subjects will be 
instructed to return all used and unused study drug containers at each  study visit. Subject 
compliance with the dosing schedule will be assessed by reconciliation of the used and unused 
study drug at each clinic visit and review of the dosing diaries. The quantity dispensed, returned, 
used, lost, etc. must be recorded on the  dispensing log provided.   
Compliance will be monitored and documented by site personnel on the appropriate form. The 
site personnel will question the subject regarding adherence to the dosing schedule by reviewing 
the dosing diaries, recording the number of tablets  (and strengths , if applicable)  returned, the 
date returned, and determining treatment compliance (at least 80% of the total assigned dose)  
before dispensing new medication to the study subject.  
9 STUDY PROCEDURES  
9.1 Pre-screening for HRAS Mutation  
The pre -screening for HRAS m utation procedures to be performed in subjects enrolled in KO -
TIP-007 are outlined in  Table 1 . 

Tipifarnib   
CTP KO-TIP-007          Page 61  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   Kura Oncology, Inc. or its designee will assign a subject number identifier for each subject that 
is enrolled into the study  upon compl etion of informed consent for prescreening . Identification of  
HRAS mutations may be conducted using NGS gene panels that generate mutational information 
on tumor related genes , including variant allele frequency .  
Screening for HRAS mutation can occur at any time prior to initiating tipifarnib treatment in this 
study  and may be performed in subjects who are not yet fully eligible for KO -TIP-007, e.g. pre -
screening for HRAS mutations may be performed in subjects currently receiving platinum -based 
or other 1 firsttherapy.  Because a tumor’s biology changes over time and in response to anti -
cancer therapies, it is recommended that testing is performed on tumor tissue obtained 
subsequent to the most recent prior; if it is not possible to obtain tissue meeting th is criterion 
(clinical risks too high, patient refusal, etc), the reason must be documented .  If several tumor 
samples are available, HRAS testing should be performed on the most recently obtained tumor 
sample.   
Subjects are required to have a missense HRA S mutation for enrollment in AIM -HN, the 
tipifarnib treatment portion of KO -TIP-007.  Subjects without a missense HRAS mutation may 
participate in SEQ -HN, the noninterventional portion of KO -TIP-007 (see  Section 9.1.4  and 
Section  9.3).  Upon determination of subject HRAS mutational status, subject will proceed to 
cohort -specific screening procedures for participation in AIM -HN (HRAS mutant HNSCC 
subjects , Section  9.2.1 ) or SEQ -HN (HRAS wildtype HNSCC subjects , Section  9.3.1 ). 
9.1.1 Subjects With Known HRAS Mutation  
If a subject has had HRAS mutation testing as part of their medical care or through another study 
protocol, the following circumstances need to be  considered prior to enrolment into  the AIM -HN 
part of KO -TIP-007: 
• If HRAS mutation data were obtained subsequ ent to the most recent prior therapy , and  
obtained using a Sponsor approved test, these data may be used for enrollment.  Re-biopsy 
should be considered for tumor tissue not meeting th is requirement. If re-biopsy is not 
possible, the clinical justification should be recorded . Procedures as outlined in Section 
9.1.2  regarding obtaining tumor material for potential confirmatory testing at a central 
laboratory should be followed.  
• If HRAS mutation data were obtained us ing a test which is not approved by the Sponsor, 
these data may not be used for enrollment.  In such cases, HRAS testing procedures 
outlined in Section 9.1.2  should be followed for study eligibility.  
In addition, the following  procedures are to be performed in all subjects with known HRAS 
mutation status irrespective of method for previous HRAS testing:  
• ICF for HRAS pre -screening: Subjects must be consented for study participation and should 
be documented in the subject’s medic al chart.  

Tipifarnib   
CTP KO-TIP-007          Page 62  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   • Collection of a blood sample for the analysis of HRAS mutations   
 in plasma and shipment to a Sponsor designated 
laboratory.  
• Collection of HRAS mutation data including:  
o Anatomical biopsy site, dat e of sampling and setting (e.g. primary, locally advanced, 
metastatic lesion)  
o HRAS mutation  in sample  including variant allele frequency  or HRAS wildtype status  
o Test platform (e.g. NGS, PCR, other)  
 
9.1.2 Subjects Without Known HRAS Mutational Status: Testing for HRAS 
mutation  at a Sponsor Designated Laboratory  
The following procedures must be performed:  
• ICF for HRAS pre -screening: Subjects must be consented for study participation and should 
be documented in the subject’s medical chart.  
• Collection and s hipment of tumor material for HRAS mutation testing at a Sponsor 
designated laboratory.  Additional details regarding HRAS testing procedures will be 
provided in a separate laboratory manual.  
• Collection of a blood sample for the analysis of HRAS mutations   
 in plasma  and shipment to a Sponsor designated 
laboratory.  
• Collection of HRAS mutation data including:  
o Anatomical biopsy site, date of sampling and setting (e.g. primary, locally advanced, 
metastatic lesio n) 
o HRAS mutation  in sample including variant allele frequency or HRAS wildtype status  
 
9.1.3 Subjects Without Known HRAS Mutational Status: Local testing for 
HRAS mutation using a Sponsor approved test:  
Subjects identified as HRAS mutant HNSCC using a Sponsor approved test used by the 
institution are eligible for enrollment in KO -TIP-007 based on the results of local HRAS testing.   
In order to proceed with approved local testing, the following procedures  must be performed:  
• ICF for HRAS pre -screening:  Subjects must be consented for study participation and should 
be documented in the subject’s medical chart.  

Tipifarnib   
CTP KO-TIP-007          Page 63  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   • Collection and shipment of tumor material , preferably from the same sample as was used 
for local tes ting, for HRAS mutation testing at the central laboratory  during AIM -HN 
Screening .  Additional details regarding HRAS testing procedures will be provided in a 
separate laboratory manual.  
• Collection of a blood sample for the analysis of HRAS mutations   
 in plasma and shipment to a Sponsor designated 
laboratory.  
• Collection of HRAS mutation data including:  
o Anatomical biopsy site, date of sampling and setting (e.g. primary, locally advanced, 
metastatic lesion)  
o HRAS mutation  in sample  including variant allele frequency  or HRAS wildtype status  
o Test platform (e.g. NGS, PCR, other)  
9.1.4 Subjects who have HNSCC without HRAS mutation  
Subjects who are determined to be HRAS wildtype through prescreening  testing  in KO -TIP-007 
will be offered participation in the SEQ -HN.  Further details on the study procedures for subjects 
participating in SEQ -HN can be fou nd in Section  9.3. 
9.2 AIM -HN 
The evaluations to be performed for subjects enrolled  in AIM -HN are summarized in  Table 2 .  
The following subsections apply to subjects participating in AIM -HN. 
9.2.1 Screening Procedures  
A signed ICF must be obtained before any study -specific screening evaluations are performed 
and should be documented in the subject’s medical chart.   A separate consent will be obtained 
for HRAS mutation pre-screening procedures  and is further detailed in Section  9.1. 
The following evaluations and procedures will be perfo rmed within 28 days prior to the first  
study drug administration (Cycle 1 Day 1):  
• Signed  ICF/ patient informed consent (PIC) and other forms required by local regulation 
(e.g. the Health Insurance Portability and Accountability Act (HIPAA)/Data Protection Act 
(DPA) ) 
• Tumor assessments:  
o CT scan with a contrast agent is the preferred imaging method and the same technique 
should be used at baseline and post -treatment assessments. CT scan coverage at 
screening  should encompass scans of the neck (including the skull base), chest and 
abdomen (including the liver and adrenals).  Any other areas of disease involvement 
should be scanned based on the subject’s signs and symptoms.  

Tipifarnib   
CTP KO-TIP-007          Page 64  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   o The presence of at least one measurable target lesion per RECIST v1.1 mus t be 
confirmed by local radiology prior to enrollment. Subjects without at least one 
measurable target lesion confirmed by local radiology will not be enrolled into AIM -HN. 
Note: Confirmation of RECIST v1.1 measurable disease by local radiology  is required  
for study eligibility.  
o Transfer of baseline tumor scans , historical tumor scans (see below)  and related clinical 
information to IRF.   
 Efforts should be made to obtain h istorical scans to document tumor progression .  If 
additional time is needed to obtain the historical scans, these scans should be 
submitted no later than the first tumor response assessment (approximately 8 weeks 
following Cycle 1 Day 1) .  These historical scans should include the scans that 
demonstrate most recent progression that o ccurred on the prior regimen and the scan 
demonstrating the nadir prior to the progression.  Confirmation of the prior 
progression will not be confirmed centrally, however these scans will be used by IRF 
for comparison of prior treatment effect with the ba seline scans.  
• Demographics  
• Disease  history including:  
o Primary diagnosis , date of initial diagnosis, stage of disease at diagnosis, anatomical 
disease site(s) at diagnosis  
o Current stage of disease  
o Smoking and betel nut exposure  
o Alcohol use  
o HPV status  
o Other relevant medical history  
• First line systemic treatment for recurrent or metastatic HNSCC  including:   
o Anatomical (organ) disease site(s) at the time of first line therapy  for recurrent or 
metasta tic disease  
o Performance status at the time of first line therapy for treatment of recurrent or 
metastatic disease.  
o Name of treatment  
o Dates of treatment (start, end).  
o Treatment outcome (response and response criteria), duration of response  
o Date of progres sion   

Tipifarnib   
CTP KO-TIP-007          Page 65  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   • Prior cancer therapy(ies) for HNSCC including:  
o Name(s) of treatment(s), dates (start, end)  
o Treatment outcome (response and response criteria), duration of response  
o Date of progression(s).  
o Prior cancer surgery(ies) for HNSCC including date(s) of sur gery.  
o Prior/current radiological treatments for HNSCC including anatomical site(s) and date(s) 
of radiation treatment.  
• Buccal swab  
• Collection and shipment of tumor material for HRAS mutation testing and pathology 
review at the central laboratory.  Tumor m aterial for central evaluation should preferentially  
be shipped by Cycle 1 Day 1.   Additional details regarding central HRAS testing and 
pathology review procedures will be provided in a separate laboratory manual.  
o Subject enrollment may be based on local pathology assessment and HRAS testing 
results from a Sponsor designated laboratory or Sponsor approved local tests.   
• Concomitant medications  
• Assessment of AEs, including ongoing AEs  
  
The following evaluations and procedures will be performed within 14 days prior to the first 
administration of study drug (Cycle 1 Day 1):  
• Complete physical examination  
• Height  
• Weight  
• Vital signs (heart rate, blood pressure, temperature)  
• 12-lead ECG  
• ECOG perfor mance status.  
  
• Laboratory tests: Fasting is not required.  
o Serum Chemistry  
o Hematology  
o Coagulation  
o Urinalysis   

Tipifarnib   
CTP KO-TIP-007          Page 66  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   The following evaluations and procedures will be performed within 72 hours  prior to the first 
administration of  study drug (Cycle 1 Day 1):  
• Serum/urine pregnancy test for females of child -bearing potential only  
• Confirmation that the subject continues to meet laboratory prescribed eligibility criteria  
If the subject meets all eligibility criteria after the screening  visit(s), the study site will complete 
the inclusion/ exclusion criteria evaluation and submit the enrollment form to the Sponsor or 
designee.  
9.2.2 Day 1 of Cycle 1  
The following assessments will be conducted  before the first dose of tipifarnib  on Day 1 of Cycle 
1: 
• Collection of weight and vital signs (heart rate, blood pressure, temperature)  
• ECOG performance status  
• Symptom based physical examination  
• Completion of Quality of Life assessment questionnaires  
• Laboratory tests: Fasting is not required.  Laboratory tests do not need to be repeated on 
Cycle 1 Day 1 if the laboratory tests to confirm continued subject eligibility were conducted 
within 72 hours prior to the first dose of tipifarnib , and upon review the tests confirm 
subject’s continued eligibility for treatment .   
o Serum Chemistry  
o Hematology  
Subjects will be administered the first dose of tipifarnib ( 600 mg) with food. Time of dos ing is to 
be recorded.  
The following assessments will be conducted  after the first dose of tipifarnib  on Day 1 of Cycle 
1: 
    
  
  
  
• Assessment of AEs  
• Concomitant medications  
• Subjects will continue to self -administer tipifarnib twice a day (approximately every 12 
hours, same time every morning and evening) with a meal  on days 1 – 7 and days 15 – 21 

Tipifarnib   
CTP KO-TIP-007          Page 67  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   in 28 -day treatment cycles (i.e. alt ernating week schedule). The interval between dosing 
should not be less than 8 hours.  
9.2.3 Day 7 of Cycle 1   
(required for Denmark  only; all other regions should perform as  clinically indicated)  
Subjects should self -administer tipifarnib prior to the Cycle 1 Day 7 visit.    
The following procedures will be performed at this visit:   
• Serum  Chemistry   
• Hematology    
9.2.4 Day 1 ( ± 2 days) of Cycle 2  
Subjects should self -administer tipifarnib prior to the Cycle 2 Day 1 visit.   
 
   
The following procedures will be performed at this visit:  
• Collection of weight and vital signs (heart rate, blood pressure, temperature)  
• ECOG performance status  
• Symptom based physical examination  
• Completion of Quality of Life assessment questionnaires  
• Laborat ory Tests: Fasting not required.  
o Serum Chemistry  
o Hematology  
o Serum/urine pregnancy test for females of child -bearing potential only  
    
  
  
  
• Concomitant medications  
• Assessment of AEs  
In addition to the above procedures, the clinical site will conduct a drug accountability review on 
the returned empty bottles and  unused medications and will also review the dosing diaries to 
assess compliance with the dosing schedule . 

Tipifarnib   
CTP KO-TIP-007          Page 68  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   9.2.5 Day 1 ( ± 2 days) of Cycle 3 and Beyond  
The following procedures will be performed at this visit:  
• Collection of weight and vital signs (heart rate, bl ood pressure, temperature)  
• ECOG performance status  
• Symptom based physical examination  
• Completion of Quality of Life assessment questionnaires  
• Laboratory Tests: Fasting not required.  
o Serum Chemistry  
o Hematology  
o Serum/urine pregnancy test for females of child -bearing potential only  
  
   
  
  
  
• Concomitant medications  
• Assessment of AEs  
In addition to the above procedures, the clinical site will conduct a drug accountability review on 
the returned empty bottles an d unused medications and will also review the dosing diaries to 
assess compliance with the dosing schedule . 
9.2.6 Tumor Response Assessment Visits  
Tumor response assessment should occur approximately every 8 weeks  (± 5 days)  for the first 12 
months  of a subject’ s participation in AIM -HN; thereafter, tumor response assessment should 
occur  approximately every 12 weeks (± 5 days) until disease progression. The tumor response 
assessment schedule (every 8  or 12 weeks) should be maintained regardless of dosing delays o r 
additional imaging assessments performed.  
The following procedures will be performed at this visit:  
• Radiographic Imaging:  
o CT scan with a contrast agent is the preferred imaging method and the same technique 
should be used at baseline and post -treatment assessments. CT scan coverage should 
encompass scans of the neck (including the skull base), chest and abdomen (including 

Tipifarnib   
CTP KO-TIP-007          Page 69  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   the liver and adrenals).  Any other areas of disease involvement should be scanned based 
on the subject’s signs and symptoms.  
o Transfer  of tumor scans and related clinical information to  IRF 
  
  
 
   
  
   
  
  
  
  
 
 
   
  
• Concomitant medications  
• Assessment of AEs  
  
9.2.7 End of Treatment Visit  
The following assessments will  occur approximately 30 days (±7 days) after the last 
administration of  study drug  or immediately before the administration of another anti -cancer 
drug, whichever takes place first : 
• Complete physical examination  
• Weight  
• Vital signs (heart rate, blood pressure, temperature)  
• ECOG performance status.  
• Completion of Quality of Life assessment  questionnaires  
• Laboratory tests: Fasting is not required.  
o Serum Chemistry  
o Hematology  

Tipifarnib   
CTP KO-TIP-007          Page 70  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   o Serum/urine pregnancy test for females of child -bearing potential only  
• Concomitant medications  
• Assessment of AEs  
• Radiographic Imaging:  Applies only for subjects who termi nated treatment for reasons 
other than death or disease progression .  In these subjects, imaging should be performed at 
the End of Treatment visit if not done within the prior 8 weeks or if a tumor assessment is 
required for the confirmation of response.  
o CT scan with a contrast agent is the preferred imaging method and the same technique 
should be used at baseline and post -treatment assessments. CT scan coverage should 
encompass scans of the neck (including the skull base), chest and abdomen (including 
the liver and adrenals).  Any other areas of disease involvement should be scanned based 
on the subject’s signs and symptoms.  
o Transfer of tumor scans  and related clinical information  to IRF 
• Conduct drug accountability and diary review on the returned empty bottles and unused 
medications.  
  
9.2.8 Follow up Visit  
Follow up visit(s) are required only for subjects who terminated treatment for reasons other than 
disease  progression and should occur approximately every 8  or12 weeks  (± 5 days)  until disease 
progression.  If the subject initiates a new anticancer therapy  without evidence of disease 
progression by RECIST v1.1 criteria, tumor assessments should continue until there is evidence 
of disease progression unless withdrawal of subject’s consent to study procedures.  
The assessments to be conducted at these visits a re: 
• Ascertainment of details of any new anti -cancer treatments /surgeries ( name, dates (start, 
end), treatment outcome (response and response criteria), duration of response ) 
• Radiographic Imaging: to be performed if not done within the prior 8 weeks or if a  tumor 
assessment is required for the confirmation of response.  
o CT scan with a contrast agent is the preferred imaging method and the same technique 
should be used at baseline and post -treatment assessments.  CT scan coverage should 
encompass scans of the neck (including the skull base), chest and abdomen (including 
the liver and adrenals).  Any other areas of disease involvement should be scanned based 
on the subject’s signs and symptoms.  
o Transfer of tumor scans and related clinical information to IRF 

Tipifarnib   
CTP KO-TIP-007          Page 71  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   • Assessments of AEs and concomitant medications may also be conducted if AEs were not 
resolved at the time of the End of Treatment visit.  
  
9.2.9 Follow Up Contact  
Upon disease progression  or withdrawa l of consent for additional study procedures , follow up 
contact with the subject and/or caregiver(s) (e.g. electronic technology -based, telephone or in 
person) is to occur approximately every 12 weeks (± 1 week) for survival  and the use of 
subsequent thera py until End of Study (see  Section  6.7.1 ). Information on survival and 
subsequent anticancer therapy for HNSCC will be collected including name, dates (start, end), 
treatment outcome (response and response criteria), duration of response, date of progression. 
Information will also be collected on subsequent cancer surgery(ies) for HNSCC including date 
of surgery.  Information will be collected on subsequent radiological treatments for HNSCC 
including anatomical site(s) and date (s) of radiation treatment.  
9.3 SEQ -HN 
The evaluations to be performed for HRAS wildtype HNSCC subjects enrolled in SEQ -HN are 
summarized in  Table 3 .  The following subsections apply to HRAS wildtype HNSCC subjects  
participating in SEQ -HN. 
9.3.1 Screening Procedures  
A signed ICF must be obtained before any study -specific evaluations are performed and should 
be documented in the subject’s medical chart.   A separate consent will be obtained for HRAS 
mutation pre-screening a nd is further detailed in  Section 9.1 . 
The following evaluations and procedures will be performed during screening : 
• Signed ICF for participation in the SEQ -HN portion of this study  
• Collection of HRAS wildtype status  (blood sample and tissue sample)  
• Inclusion/exclusion criteria evaluation  
9.3.2 Study Enrollment   
The following information will be collected from enrolled subjects:  
• Demographics  
• Disease  history including:  
o Primary diagnosis , date of initial diagnosis, stage of disease at diagnosis, anatomical 
disease site(s) at diagnosis  
o Current stage of disease  

Tipifarnib   
CTP KO-TIP-007          Page 72  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   o Smoking and betel nut exposure  
o Alcohol use  
o HPV status  
o Other relevant medical history  
• First line systemic treatment for recurrent or metastatic HNSCC  including:   
o Anatomical (organ) disease site(s) at the time of first line therapy  for recurrent or 
metastatic disease  
o Performance status at the time of first line therapy for treatment of recurrent or 
metastatic disease.  
o Name of treatment  
o Dates of treatment (start, end ).  
o Treatment outcome (response and response criteria), duration of response  
o Date of progression   
In subjects  who have not yet received or completed first line systemic treatment for 
recurrent or metastatic HNSCC, first line systemic treatment  information  (anatomical 
disease site, performance status, names and dates of treatment, treatment outcome , duration 
of response  and date of progression) will be collected through follow -up contact (See 
Section 9.3.4 ). 
• Other prior cancer therapy(ies) for HNSCC including:  
o Name(s) of treatment(s), dates (start, end)  
o Treatment outcome (response and response criteria), duration of response  
o Date of progressions  
o Prior cancer surgery(ies) for HNSCC including date of surgery.  
o Prior/current radio logical treatments for HNSCC including anatomical site(s) and date(s) 
of radiation treatment.  
9.3.3 On Study Visit  
A blood sample will be collected from all control subjects during Weeks 16 – 24 since the time 
of SEQ -HN enrollment for the evaluation of acquired HRAS mutations during standard of care 
treatment , including surveillance or on treatment break .  If a subject experiences disease 
progression prior to Weeks 16 - 24, the blood sample for HRAS mutational analysis should be 
collected at that time.     

Tipifarnib   
CTP KO-TIP-007          Page 73  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   Subjects who are found to have an HRAS mutation following enrollment will be offered 
participation in AIM -HN (assuming all other eligibility criteria are met).   
9.3.4 Follow Up Contact  
Follow up contact with the subject and/or caregiver(s) (e.g. electronic tech nology -based, 
telephone or in person) is to occur approximately every 12 weeks (± 1 week) from the time of 
study enrollment through  second line regimen initiation , consent withdraw  or completion of 
AIM -HN.  Additional follow up of the matched HRAS wildtype  HNSCC patients enrolled into 
SEQ -HN may continue until all AIM -HN objectives are completed and KO -TIP-007 end of 
study is reached.  
Information on survival and subsequent anticancer therapy for HNSCC may be collected by  
phone including name, dates (start, end), treatment outcome (response and response criteria), 
duration of response, date of progression. Information will also be collected on subsequent 
cancer surgery(ies) for HNSCC including date of surgery.  Information will be collected on 
subsequent radi ological treatments for HNSCC including anatomical site(s) and date(s) of 
radiation treatment.  
10 ASSESSMENT OF EFFICACY  
Table 1 , Table 2 , and Table 3  summarize  the study required  evaluations.  
10.1 Efficacy Parameters  
The following subsections apply only to subjects participating in AIM -HN. 
10.1.1  Efficacy Variables  
Objective response (complete response and partial response) as determined by the subject’s best 
tumor response, duration of response, and time to progress ion will be assessed using RECIST 
v1.1(Appendix I ) by IRF.  Confirmation of response is required.   An IRF charter  providing  the 
specific procedures  will be filed with IRB s/IECs and regulatory autho rities .  
Local/Investigator tumor response assessment s will be collected and used to inform patient care 
decisions .   
 
  
10.1.2  Method and Timing   
Radiological assessments of the  tumor lesions will be made at screening (within 4 weeks prior to  
first study dr ug administration on Cycle 1 Day 1) and at least once approximately every 8 weeks 
(± 5 days)  for 12  months , thereafter once approximately every 12 weeks  (± 5 days).   Additional 
tumor assessments may be conducted at the judgment of the Investigator.  

Tipifarnib   
CTP KO-TIP-007          Page 74  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   Radiological assessments will be discontinued at the time of  tumor progression. Subjects who 
discontinue treatment for reasons other than disease progression must continue tumor 
assessments until disease progression . Collection of response data may continue upon initiation 
of another anticancer therapy unless the s ubject withdraw s their  consent to study procedures .  
Radiological assessments may also be conducted at treatment discontinuation (End of Treatment 
visit) if the reason for the treatment termination is other than disease progression and a tumor 
assessment w as not done within 8 weeks  before treatment discontinuation ( assessment must be 
conducted before subsequent  anti-tumor therapy is started).  Scans at the End of Treatment visit 
will be also conducted if required to confirm response to treatment.  
Lesions to be included in the t umor assessments should follow RECIST v1.1  (See Appendix I). 
CT scan  with a contrast agent is the preferred imaging method and the same technique should be 
used at screening and post -treatment assessments. CT scan coverage at screening  should 
encompass scans of the neck (including the skull base), chest and abdomen (includin g the liver 
and adrenals).  Any other areas of disease involvement should be scanned based on the subject’s 
signs and symptoms.  
Subjects with contrast allergy or renal insufficiency may use non -contrast CT or MRI, whichever 
is required to adequately assess  all disease. For subjects who develop a contraindication to 
contrast after screening scans are performed with a contrast agent, the decision to use non -
contrast CT or MRI (enhanced or non -enhanced) should be based on tumor type, anatomic 
location of disea se and should be optimized to allow for comparison to the prior scans if 
possible.  The one exception where MRI would not be recommended is for the evaluation of 
parenchymal lung metastases.  In this instance, CT would be preferred.  If imaging of the brai n is 
indicated, MRI of the brain with and without gadolinium should be performed for optimal 
evaluation of the brain.  If MRI is medically contraindicated, CT of the brain with and without 
contrast would be suggested.  Guidelines for imaging and instructio ns for transmission of the 
images to IRF will be provided to each study site.  
10.2 Additional  Variables  
10.2.1  Population Pharmacokinetics  
The blood samples for population PK  analysis will be collected  from subjects participating in 
AIM -HN at the time points described in  Table 9. 

Tipifarnib   
CTP KO-TIP-007          Page 75  
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   The time and date of blood sample collection will be collected and recorded in the eCRF.  
Additionally, on study visit days when a blood sample for population PK analysis is collect ed, 
the time, date and dosage (mg) of the subject’s last dose of tipifarnib (most recent dose to the PK 
blood sample) will be collected and recorded in the eCRF.  
The total blood volume to be collected for the purpose of characterizing the population PK  of 
tipifarnib  will be approximately   Additional blood samples for the 
determination of tipifarnib plasma concentration may be collected at the discretion of the 
Investigator.  
Samples for the evaluation of  tipifarnib  concentration w ill be collected, processed and shipped as 
detailed in the Laboratory manual.  
10.2.2  Biomarkers  
Additional variables to be examined as a part of this study include somatic  mutations in 
submitted tumor tissue  and plasma samples  
 (Witzig 2017 ).  These variables may be examined in subjects enrolled in AIM -HN and in 
subjects enrolled in SEQ -HN.  
Genetic testing will be/ was performed using Sponsor approved local tests or through central 
testing designated by the Sponsor.  Samples may be submitted to a laboratory CRO if deemed 
necessary by the Investigator or Sponsor or for convenience . Genetic markers (mutation, gene 
expression) include , but are not limited to , a panel of oncogenes common ly mutated in HNSCC 
or other alterations that could be relevant for the biology or treatment of HNSCC.   Gene 
expression analyses may include  the characterization of alternative gene spliced transcripts, post -
transcriptional modifications, gene fusion s, changes in gene expression  and u nsupervised gene 
expression analyses . 

Tipifarnib   
CTP KO-TIP-007          Page 76  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   11 ASSESSMENT OF SAFETY  
The following subsections apply only to subjects participating in AIM -HN. 
11.1 Safety Parameters  
Adverse eve nts will be graded according to the NCI CTCAE  v5.0. Adverse events will be 
summarized by relationship  to study  drug and severity . The safety profile of the IP will be 
assessed through the recording, reporting and analyzing of  baseline medical conditions, AEs, 
physical examination findings including vital signs  and laboratory tests.  Comprehensive 
assessment of any apparent toxicity experienced by the subject will be  performed throughout the 
course of the study , from the time of the subject’s signature of informed  consent  for AIM -HN. 
Incidental findings on r adiological scans will not be reported  by the IRF.  Study  site personnel 
will report any AE, whether observed by the  Investig ator or reported by the subject.    
The IDMB  will review all relevant safety data on a regular basis.  
11.2 Method and Timing  
At each study  visit, the subject will be queried on changes in his/her condition. During the  
reporting period of the study  any unfavorable changes in the subject’s condition will be recorded  
as AEs, whether reported by the subject or observed by the Investigator . 
Complete, accurate and consistent data on all AEs experienced for the duration of the reporting  
period (defined be low) will be reported on an ongoing basis in the appropri ate section of the 
eCRF. Among these AEs, all SAEs must be additionally documented and reported using the 
Serious Adverse Event Report Form . It is important that each AE report include a description of 
the event, its duration (onset and  resolution dates, including time when it is important to assess 
the time of AE  onset relative to the recorded treatment administration time), its severity, its 
relationship with  the study  treatment, any other potential  causal factors, any treatment given or 
other action taken  (including dose modification or discontinuation of the IPs) and its outcome. In 
addition,  serious cases should be identified,  and the appropriate seriousness criteria documented.  
Specific guidance can be found in the eCRF completion and monitoring c onventions provided  by 
the Sponsor.  
11.2.1  Monitoring of Subjects with Adverse Events  
Any AE that occurs during the course of a clinical study  and is considered to be possibly related 
to the IP must be monitored and followed up by the Investigator until stabilization or until the  
outcome is known unless the subject is documented as “lost to follow -up”. Reasonable attempts  
to obtain this informat ion must be made and documented. It is also the responsibility of the  
Investigator to ensure that any necessary additional therapeutic measures and follow -up 
proced ures are performed. The Sponsor will actively follow -up and collect information on any  
AE th at occurs during the course of a clinical study , however while this activity will continue for  

Tipifarnib   
CTP KO-TIP-007          Page 77  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   any serious AEs until stabilization or until the outcome is known, it will be discontinued at the  
time of database lock for non -serious AEs.  
11.2.2  Pregnancy and In Ute ro Drug Exposure  
Only pregnancies considered by the Investigator as related to study  treatment (e.g. resulting from  
a drug interaction with a contraceptive medication) are considered as AEs. However,  all 
pregnancies with an estimated conception date during the study safety period must be recorded 
by convention in the AE page/section of the eCRF. The same rule applies to  pregnancies in 
female subjects and in female partners of male subjects. The Investi gator must  notify the 
Sponsor in an expedited manner of any pregnancy using the Pregnancy Report Form,  which must 
be transmitted according to the same process a s described for SAE reporting . 
Investigators must actively follow up, document and report on the  outcome of all these  
pregnancies, even if the subjects are withdrawn from the study . The Investigator must notify the 
Sponsor of these outcomes using the Pregnancy Report Form,  and in case of abnormal outcome, 
the Adverse Event Report Form when the subjec t sustains an event and the Parent -Child/Fetus 
Report Form when the child/fetus sustains an event.  
Any abnormal outcome must be reported in an expedited manner, while normal outcomes must 
be reported within 45 days from delivery.  
In the event of a pregnanc y in a subject occurring during the course of the study, the subject must 
be discontinued from study medication immediately. The Sponsor must be notified without delay 
and the subject must be followed as mentioned above.  
11.2.3  Laboratory Assessments  
All clinical  safety laboratory tests listed in the section below will be performed at local 
laboratories. Subject eligibility will be determined based on the baseline laboratory results.  
Clinically significant laboratory test abnormalities will be followed until resol ution or 
stabilization and the overall clinical outcome has been ascertained (Se e Section 11.4.5 ). 
11.2.3.1  Blood Sample Collection for General Clinical Laboratory Assessments  
Blood samples will be collected and reviewed for the follo wing clinical laboratory tests  within 
72 hours of C1D1 (or on C1D1 prior to dosing) : 
• Serum Chemistry: Glucose, Blood Urea Nitrogen (or Urea ), Creatinine, Sodium, 
Potassium, Chloride, Calcium, Magnesium, Phosphorus, Total Protein, Al bumin, Total 
Bilirubin, Alkaline Phosphatase, alanine aminotransferase (ALT) , aspartate 
aminotransferase (AST) , Gamma -Glutamyltransferase, and Lactate Dehydrogenase . 
Bicarbonate (or total CO2)  is optional.  
• Hematology: White Blood Cell Count, Red Blood Cell  Count, Hemoglobin, Hematocrit, 
Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils  

Tipifarnib   
CTP KO-TIP-007          Page 78  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   • Coagulation profile: activated partial thromboplastin time (APTT) , prothrombin 
time/international normalized ratio (PT/INR)  
11.2.3.2  Urinalysis  
Macroscopic a ssessment of the amount of protein, glucose, white blood cells and blood will be 
conducted. If abnormalities are noted, these will be recorded,  and a microscopic analysis 
conducted and recorded. If at any time, the subject’s serum creatinine is ≥ Grade 2, then a serum 
chemistry, microscopic urinalysis including the measurement of protein, glucose, blood, white 
blood cells will be conducted. If abnormalities are noted, then spot urine sodium, protein and 
creatinine should be performed to assess fracti onal so dium excretion (plasma creatinine x urine 
sodium / plasma sodium x urine creati nine) and urine protein/creatinine ratio (urine protein 
mg/urine creatinine mg ratio).  
11.2.3.3  Pregnancy Testing  
Pregnancy testing will be performed in females of child -bearing potential and testing may be 
performed on urine or serum.  If a positive urine pregnancy test is obtained, a confirmatory 
serum pregnancy test should be conducted.  If confirmatory test is pos itive, subject must 
terminate tipifarnib treatment immediately and follow pregnancy reporting guidelines outlined in 
the protocol.  
Female subjects enrolled in AIM -HN must have a negative serum or urine pregnancy test within 
72 hours prior to start of study  medication (Cycle 1 Day 1).  Pregnancy assessments will be 
performed on Day 1 of each cycle starting at Cycle 2.  
11.3 Adverse Event Reporting  
11.3.1  Procedure for Reporting Adverse Events  
The AE reporting period for safety surveillance begins when the subject is incl uded into the 
study (date of first signature of AIM -HN informed consent) and continues through the study’s 
post-treatment follow -up period, defined as approximately 30 days from the final administration 
of the study treatment or immediately before initiati on of any other anticancer therapy, 
whichever comes first.  
The Investigator is required to grade the severity/intensity of each AE. Investigators will 
reference the NCI -CTCAE v 5.0. This is a descriptive terminology that can be used for AE 
reporting. A general grading (severity/intensity) scale is provided at the beginning of the 
referenced document, and specific event grades are also provided. If a particular AE’s 
severity/intensit y is not specifically graded by the guidance document, the Investigator is to 
revert to the general definitions of Grade 1 through Grade 5 and use his or her best medical 
judgment.  
The 5 general grades are:  
• Grade 1: Mild  

Tipifarnib   
CTP KO-TIP-007          Page 79  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   • Grade 2: Moderate  
• Grade 3: Severe o r disabling  
• Grade 4: Life -threatening  
• Grade 5: Death related to AE. Note: Death (Grade 5 as defined by NCI -CTCAE version 
5.0) is mainly regarded as an outcome, to be documented as described below.  
According to the Sponsor’s convention, if a severity/inten sity of Grade 4 or 5 is applied to an 
AE, then the Investigator must also report the event as a n SAE as per Section  11.4.2 . However, a 
laboratory abnormality with a severity/intensity of Grade 4, such as low white blood cell count or 
increased ALT, is considered serious only if the condition meets one of the serious criteria 
described below.  
In the case of death, the primary cause of death (the event leading to death) should be recorded  
and reported as an SAE. “Fatal” will be recorded as the outcome of this respective event; death  
will not be recorded as separate event. Only if no cause of death can be reported (e.g., sudden  
death, unexplained death), the death per se might be reported as an SAE.  
Investigators must also systema tically assess the causal relationship of AEs to the IP. Decisive 
factors for the assessment of causal  relationship of an AE to the study  treatments include, but 
may not be limited to, temporal  relationship between the AE and the study  treatments, known 
side effects of the study  treatments,  medical history, concomitant medications and procedures, 
course of the underlying disease  and study  procedures.  
11.3.2  Procedure for Reporting Serious Adverse Events  
In the event of any new SAE occurring during the reporting period, the Investigator must 
immediately (i.e. within a maximum of 24 HOURS after becoming aware of the event) inform 
the person(s) identified in the Serious Adverse Event Report Form by telephone , by fax or by 
email. When an event (or follow -up information) is reported by telephone, a written report must 
be sent immediately thereafter by fax or e -mail. Reporting procedures and timelines are the same 
for any new information on a previously reported  SAE. For names, addresses, telephone and fax 
numbers for SAE reporting, see information included in the Serious Adverse Event Report Form. 
All written reports should be transmitted using the Serious Adverse Event Report Form, which 
must be completed by th e Investigator following specific completion instructions.  
The AE section of the eCRF must be completed and a copy of the information transmitted with 
the Serious Adverse Event Report Form. Other relevant pages from the eCRF may also be 
provided (e.g. medi cal history, concomitant drugs). The Investigator/Reporter must respond to 
any request for follow -up information (e.g. additional information, outcome and final evaluation, 
specific records where needed) or to any question the Sponsor may have on the SAE w ithin the 
same timelines as described for initial reports. This is necessary to permit a prompt assessment of 
the event by the Sponsor to allow for strict regulatory timelines associated with expedited safety 
reporting obligations.  

Tipifarnib   
CTP KO-TIP-007          Page 80  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   11.3.3  Safety Reporting to Heal th Authorities, Institutional Review Boards and 
Investigators  
The Sponsor will send appropriate safety notifications to Health Authorities in accordance with 
applicable laws and regulations. The Investigator must comply with any applicable site -specific 
requirements related to the reporting of SAEs (and in particular deaths) involving his/her 
subjects to the IRB/IEC that approved the study.  
In accordance with ICH GCP guidelines, the Sponsor will inform the Investigator of “findings 
that could adversely affe ct the safety of subjects, impact the conduct of the study or alter the 
IRB/IEC’s approval/favorable opinion to continue the study.” In particular and in line with 
respective regulations, the Sponsor will inform the Investigator of AEs that are both seriou s and 
unexpected and are considered to be related to the administered product (“suspected unexpected 
serious adverse reactions”, SUSARs). The Sponsor will also provide SUSAR information to the 
Competent Authorities in all Member States concerned and Ethics  Committees in compliance 
with SUSAR reporting outlined in the European Directive 2001/20/EC.  The Investigator should 
place copies of safety reports in the Investigator Site File. National regulations with regards to 
safety reporting notifications to inve stigators will be taken into account. When specifically 
required by regulations and guidelines, the Sponsor will provide appropriate safety reports 
directly to the concerned lead IRB/IEC and to the Competent Authorities in all Member States 
concerned and w ill maintain records of these notifications. When direct reporting by the Sponsor 
is not clearly defined by national or site -specific regulations, the Investigator will be responsible 
for promptly notifying the concerned  IRB/IEC of any safety reports provi ded by the Sponsor and 
of filing copies of all related correspondence in the Investigator Site File.  
11.4 Definitions  
11.4.1  Adverse Events  
An AE is any untoward medical occurrence in a patient  or clinical investigation subject  
administered a pharmaceutical product, which does not necessarily have a causal relationship  
with this treatment. An AE can therefore be any unfavorable and unintended sign (including an  
abnormal laboratory finding), symptom, or disease temporally associated with the use  of a 
medicinal product, whether or not considered related to the medicinal product.  In cases of 
surgical or diagnostic procedures, the condition/illness leading to such a procedure is  considered 
as the AE rather than the procedure itself.  In case of a fat ality, the cause of death is considered as 
the AE, and the death is considered as its  outcome.  
Relatedness of an AE will be evaluated as follows:  
• Not related: Not suspected to be reasonably related to the IPs. AE could not medically  
(pharmacologically/clin ically) be attributed to the IPs under study  in this clinical  study  
protocol. A reasonable alternative explanation must be available.  

Tipifarnib   
CTP KO-TIP-007          Page 81  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   • Related: Suspected to be reasonably related to the IPs. AE could medically  
(pharmacologically/clinically) be attributed to  the IPs under study  in this clinical  study  
protocol.  
11.4.2  Serious Adverse Event  
An SAE is any untoward medical occurrence that at any dose:  
• Results in death.  
• Is life -threatening.  NOTE: The term “life -threatening” in this definition refers to an event 
in which the subject is at  risk of death at the time of the event; it does not refer to an 
event that hypothetically might cause  death if it were more severe.  
• Requires inpatient hospitalization or prolongation of existing hospitalization.  
• Results in  persisten t or significant disability/incapacity.  
• Is a congenital anomaly/birth defect.  
• Is otherwise considered as medically important.  
Important medical events that may not result in death, be life -threatening, or require  
hospitalization may be considered as SAEs w hen, based upon appropriate medical judgment,  
they may jeopardize the subject or may require medical or surgical intervention to prevent one of  
the outcomes listed in this definition. Examples of such events include allergic bronchospasm  
requiring intensiv e treatment in an emergency room or at home, blood dyscrasias or convulsions  
that do not result in subject hospitalization, or the development of drug dependency or drug  
abuse.  
For the purposes of reporting, any suspected transmission of an infectious agen t via an IP is also 
considered a serious adverse reaction and all such cases should be reported in an expedited  
manner.  
11.4.3  Events that Do Not Meet the Definition of an SAE  
Elective hospitalizations to administer, or to simplify study  treatment or study  procedures (e.g. 
an overnight stay to facilitate chemotherapy and related hydration therapy application) are not  
considered as SAEs. However, all events leading to unplanned h ospitalizations or unplanned  
prolongation of an elective hospitalization (e.g. undesirable effects of any administered  
treatment) must be documented and reported as SAEs.  
11.4.4  Events Not to Be Considered as AEs/SAEs  
Medical conditions present at the initial study visit that do not worsen in severity or frequency  
during the study  are defined as Baseline Medical Conditions and are NOT to be considered AEs.  
Progression of underlying disease is not an AE and therefore not an SAE per se, rather an  
efficacy endpoint , unless deemed to be causally related to administration of IP. However, if 

Tipifarnib   
CTP KO-TIP-007          Page 82  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   adverse signs or symptoms occur in associatio n with disease progression then these  should be 
recorded as AEs and reported as SAEs if meeting any seriousness criteria.  
11.4.5  Abnor mal Laboratory Findings and Other Abnormal Investigational 
Findings  
Abnormal laboratory findings and other abnormal investigational findings (e.g. on an ECG trace) 
should not be reported as AEs unless they are associated with clinical signs and symptoms, l ead 
to treatment discontinuation,  or are considered otherwise medically important by the 
Investigator. If an abnormality fulfills these criteria, the identified medical condition (e.g. low 
white blood cell count, increased ALT) must be reported as the AE r ather than the abnormal 
value itself.  
11.5 Adverse Event Follow -up 
All subjects will be followed -up for safety through approximately 30 days after treatment 
discontinuation or until immediately before the administration of another anticancer treatment, 
whicheve r occurs first.  Additional safety follow -up may be conducted if unresolved toxicity is 
present at the End of Treatment visit. The IDMB will provide periodic evaluations of safety and 
other data to ensure subject safety as well as the validity and scientif ic merit of the study.      
12 STATISTICAL CONSIDERATIONS   
This section outlines the statistical analysis strategy and procedures for the study. Specific  details 
of the primary and key secondary analyses  will be provided in the Statistical Analysis  Plan 
(SAP). The modified  Intent -to-Treat analysis will be the primary analysis set for efficacy 
analyses and the per-protocol analysis set will be used as the secondary population.  
12.1 Statistical Methods  
12.1.1  Efficacy  
For the AIM -HN analyses, t he estimate of the ORR will be calcu lated based on the maximum 
likelihood estimator (i.e., crude proportion of tipifarnib treated subje cts whose best overall 
response is Complete Response ( CR) or Partial Response (PR)  by IRF ) using the mITT analysis 
population set . Confirmation of response is required.  The estimate of the objective response rate  
will be accompanied by 2 -sided 95% exact binomial confidence interval.  Efficacy will also be 
evaluated among the planned 80 subjects in the per -protocol analysis set , as well as summarized 
based on Investigator assessment of tumor response.  
 
 
 
 
Time to objective response (OR) and  duration of objective response  (DOR)  will be calculated for 
tipifarnib treated subjects who achieve CR or PR.  For such subjects, the time to OR is defined as 

Tipifarnib   
CTP KO-TIP-007          Page 83  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   number of days from enrollment in AIM -HN until start of PR or CR (whichever occurs first), 
while duration of objective response is def ined as the number of days from the start date of PR or 
CR (whichever response is achieve d first) to the first date that progressive disease is objectively 
documented. Disease pr ogression will be determined by IRF using RECIST v1.1 but local 
treatmen t decisions will be made by the Investigator based on local tumor measurements and 
other clinical information . The duratio n of objective response will be right -censored for subjects 
who achieve CR or PR and meet one of the following conditions: 1)  non-protocol anticancer 
treatment started before documenta tion of disease progression, 2) death or documented disease 
progression after more than 1 m issed disease assessment visit, or 3) alive and does not have 
documentation of disease pro gression before a data an alysis cutoff date. The analyses will be 
performed as determined by the IRF using RECIST v1.1. Additional supportive analyses will be 
conducted using the investigator assessment.  
The time to OR and DOR  will be summarized descr iptively using the Kaplan -Meier method. The 
50th percentile of the Kaplan -Meier distributi on will be used to estimate the median response 
duration  and a 95% confidence interval for the median response duration will be computed . 
Progression -free survival (P FS) will be defined as the time (in months) from enrollment into 
AIM -HN to either first observation of progressive disease or occurrence of death due to any 
cause within 126 days (approximately 2 time intervals for tumor assessments) of either first 
admini stration of tipifarnib or the last tumor assessment. In subjects without a progression date 
or with a death date more than 126 days after the first administration of study drugs or the last 
tumor assessment, the PFS time should be censored on the date of l ast tumor assessment or date 
of first administration of study tipifarnib, whatever occurs last. Progression -free survival 
analyses should consider tumor assessments after treatment discontinuation or metastatic 
surgery. Survival will be defined as the time  (in months) from enrollment to the occurrence of 
death due to any cause. Sensitivity analyses for PFS and survival will be performed according to 
the FDA Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics (May 20 07). 
Survival and PFS endpoints will be summarized descr iptively using the Kaplan -Meier method. 
The 50th percentile of the Kaplan -Meier distributi on will be used to estimate the median PFS 
and overall survival  and 95% confidence intervals for the median re sponse duration will be 
computed.  
 

Tipifarnib   
CTP KO-TIP-007          Page 84  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   

Tipifarnib   
CTP KO-TIP-007          Page 85  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL    
 
 
 
 
Descriptive statistics will be primarily used to summarize the demograp hic data collected in this 
study. For continuous variables, the number of patients with non -missing data, mean, either the 
standard error or standard deviation, median, 25th percentile (first quartile), 75th percentile (third 
quartile), minimum, and maximu m will be presented. For discrete data, the frequency and 
percent distribution will be presented.  
Hierarchical testing to adjust for multiplicity will be employed, beginning with the primary 
objective and working downward until first p>0.025 1 -sided, at wh ich time testing for purposes 
of firm conclusions will stop.  
Sensitivity analyses will be performed to evaluate the robustness of statistical inferences, e.g., to 
assess the impact of missing data on the conclusions. In addition, a sensitivity analysis wil l be 
conducted to evaluate of the impact of the selected VAF cut point  on the primary and key 
secondary analyses, and  to determine the  VAF cut point  which  is most predictive of clinical 
benefit . 
 
  
  
 

Tipifarnib   
CTP KO-TIP-007          Page 86  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL    
  
 
 
 
 
 
 
 
  
12.1.2  Safety and Tolerability  
Safety and tolerability of tipifarnib will be assessed based on the following:  
• Incide nce, duration, and severity of treatment -emergent AEs , SAEs , AEs resulting in 
permanent discontinuation of study drug, and deaths within approximately 30 days from  
the last dose of study drug  (or immediately before the administration of another anti -
cancer  treatment)  
• Changes in laboratory test results  
• Changes in vital signs including blood pressure, heart rate  and temperature  
• Changes in ECG  results  
AEs will be coded using the using version 22.0 of the Medical Dictionary for Regulatory 
Activities (MedDRA)  and upversioned prior to database lock . Treatment -emergent AEs are 
defined as AE s that start on or after the first dose of study drug  and within approximately 30 
days of the last administration of study drug. AEs will be summarized by the number a nd 
percentage of subjects who experienced the event, according to syste m organ class and preferred 
term. A subject reporting multiple cases of the same AE will be counted  once within each system 
organ class and similarly counted once within each preferred term.  
Unless specified otherwise, the denominator for these ca lculations will be based on the number 
of subjects enrolled  who received at least one administration of  tipifarnib , irrespective of the 
total numb er of doses or treatment cycles administered. Th ese conventions will be appropriately 
modified to calculate AE incidence rates separately for each cycle that study therapy is 
admin istered. AE incidence rates may also be calculated based on other measures of subject 
exposure (e.g., total number of treatm ent cycles administered). AEs will also be summ arized by 
NCI CTCAE v 5.0 severity grade and by relationship to each study drug. A dditional summaries 
may also be provided for SAEs, and events resulting in the permanent discontinuation of therapy. 
All AEs wil l be included in individual subject listings.  

Tipifarnib   
CTP KO-TIP-007          Page 87  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   The incidence of grade 3 and 4 hematological tox icities (including neutropenia, 
thrombocytopenia, and anemia) will be provided by treatment  cycle and across all treatment 
cycles. The toxicity grades for laborat ory tests will be  based on NCI CTCAE v 5.0. The use of 
blood transfusions (platelets, red bl ood cells) and/or growth factor support will be reported.  
Vital sign results (heart rate, blood pressure  and temperature) will be summarized descriptively 
for each scheduled and unscheduled proto col time point. Changes will be calculated relative to 
the assessments at baseline and on the first day of each cycle of therapy.  
12.1.3  Population Pharmacokinetics  
Data collected in this study will be pooled with PK and clinical da ta from other tipifarnib studies 
to perform a population PK analysis. Details and methodology for this analysis will be described 
in the Population PK Statistical Analysis Plan. The population PK results will be reported 
separately from the KO -TIP-007 CSR.  
12.2 Subject Population(s) for Analysis  
Details on any additional analysis population sets will be provided in the S AP. 
12.2.1  Efficacy Analysis  
The mITT population will include all subjects who received at least one dose of tipifarnib and 
will be use d for the primary efficacy analysis . Subjects who do not have IRF confirmed evidence 
of RECIST v1.1 measurable disease at baseline will be excluded.  
 
 
 
 
   
Dropouts will not be replaced.  For the primary  efficacy  analysis,  all subjects with  missing 
response  status will be classified as treatment failures.   
12.2.2  Safety Analysis  
The mITT  population will be used for the analysis of safety data.  At least one  laboratory or vital 
sign measurement obtained subsequent to at least one dose of study drug is required for i nclusion 
in the analysis of a speci fic safety parameter. To assess change from baseline, a baseline 
measurement is also required.  

Tipifarnib   
CTP KO-TIP-007          Page 88  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   12.3 Significance  
All confidence intervals will be 95% . Any reported p -values reported as a part of secondary or 
exploratory analyses will be considered descriptive in nature.  

Tipifarnib   
CTP KO-TIP-007          Page 89  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   12.4 Term ination Criteria  
The IDMB will consider the efficacy and futility stopping boundaries stated above as a guideline 
in evaluating the trial results with respect to ORR of tipifarnib.  In making a recommendation to 
terminate the study for any reason, the IDMB  will also consider information on safety endpoints, 
as well as consistency of outcomes for secondary endpoints.  
12.5 Accountability Procedure  
No data will be imputed; all analyses and summaries will be based on observed data only, and no 
data will be excluded.   
12.6 Deviation Reporting  
If, after the study has begun, but prior to the final analysis, importa nt changes are made to the 
protocol that affect principal features of the primary or key secondary analyses, then the protocol 
and/or SAP will be amended, as appro priate. Any other changes made to the planned analyses 
after the protocol and SAP have been finalized, along with an explanation as to when and why 
they occurred, will be listed in the Clinical Study Report (CSR) for the study. Post hoc 
exploratory analyse s will be clearly identified in the CSR.  
13 Regulatory, Ethical, and Study Oversight Considerations  
13.1 Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with the following:  
Consensus ethical principles derived from international guidelines including the Declaration of 
Helsinki and CIOMS International Ethical Guidelines  
Applicable International Council for Harmonisation (ICH) GCP Guidelines  
Applicable laws and regulations  
The protocol, protocol  amendments, ICF, IB, and other relevant documents ( e.g., advertisements) 
must be submitted to an IRB/IEC by the Investigator and reviewed and approved by the IRB/IEC 
before the study is initiated.  
Any amendments to the protocol will require IRB/IEC approv al before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study patients.  
The Investigator will be responsible for the following:  
Providing written summaries of the status of the study to  the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by the 
IRB/IEC  
Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC 
procedures  

Tipifarnib   
CTP KO-TIP-007          Page 90  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   Providing oversight of th e conduct of the study at the site and adherence to requirements of 
21 Code of Federal Regulation (CFR), ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local regulations  
13.2 Financial Di sclosure  
Investigators and sub -investigators will provide the Sponsor with sufficient, accurate  financial 
information as requested to allow the Sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regu latory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.  
13.3 Informed Consent Process  
The Investigator or his/her representative will explain  the nature of the study to the patient and/or 
his/her legally authorized representative and an swer all questions regarding the study.  
Patients or their guardians/legal representatives must be informed that the patient’s participation 
is voluntary. Patient s or their legally authorized representative (parent or other legal guardian)  
will be required to sign a statement of informed consent that meets the requirements of 
21 CFR  50, local regulations, ICH guidelines, Health Insurance Portability, and Accountabi lity 
Act requirements, where applicable, and the IRB/IEC or study center.  
As used in the protoc ol, the term “informed consent” includes all informed assent given by 
patients, informed permission by legally authorized representative, or, as applicable, info rmed 
consent by the patient during study participation.  
The medical record m ust include a statement that written informed consent was obtained before 
the patient was enrolled in the study and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF.  
Patients must be reconsented to the most current version of the ICF(s) during their participation 
in the study.  
A copy of the ICF(s) must be provided to the patient or the patient’s l egally authorized 
representative.  
A patient who is rescreened is not required to sign another ICF unless an updated ICF is 
available.  
13.4 Data Protection  
Patients will be assigned a unique identifier by the Sponsor. Any patient records or datasets that 
are tra nsferred to the Sponsor will contain the identifier only; patient names or any information 
which would make the patient identifiable will not be transferred.  
The patient must be informed that his/her personal study -related data will be used by the Sponsor 
in accordance with local data protection law. The level of disclosure must also be explained to 
the patient.  

Tipifarnib   
CTP KO-TIP-007          Page 91  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   The patient must be informed that his/her medical records may be examined by Clinical Quality 
Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate 
IRB/IEC members, and by inspectors from regulatory authorities.  
13.5 Dissemination of Clinical Study Data  
Study -related information and study results may be posted on the US National Institutes of 
Health websit e www.clinicaltrials.gov , the EU websit e www.clinicaltrialsregister.eu/ , or other 
publicly acces sible websites as appropriate and in accordance with local regulations.  
13.6 Data Quality Assurance  
All patient data relating to the study will be recorded in an eCRF unless transmitted to the  
Sponsor or designee electronically ( e.g., laboratory data). The Inve stigator is responsible for 
verifying that data entries are accurate and correct by physically or electronically signing the 
eCRF.  
The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.  
The In vestigator must permit study related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents.  
The Sponsor or designee is responsible for the data management of this study including quality 
checking of the data.  
Study monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of patients ar e being protected; and that the study is being 
conducted in accordance with the currently approved protocol and any other study agreements, 
ICH GCP, and all applicable regulatory requirements. Study monitors will communicate with 
investigational sites on a  regular basis regarding the study and all protocol deviations will be 
appropriately documented by the Investigator or designee, and study monitors.  
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by t he Investigator for 5  years after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during the 
retention period without the written approval of the Sponsor. No records may be transferred to 
another location or party without written notification to the Sponsor.  
13.6.1  Data Quality and Integrity Monitoring  
Customized to the needs of the study, real time data quality and integrity monitoring will be 
employed as part of the risk based central statistical monitoring. The monitoring will allow for 
optimal and multi -angle real time data quality assessments using various multivariate pattern 
detection algorithms powered by advanced interactive data visualization and root cause analysis 
modules. The monitoring will specifically be focused on the site and geography levels leading to 
early identification of accumulati ng data risks and issues.    

Tipifarnib   
CTP KO-TIP-007          Page 92  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   13.7 Source Documents  
Source docu ments provide evidence for the existence of the patient and substantiate the integrity 
of the data collected. Source documents are filed at the investigational site.  
The Investigator or designee will  prepare and maintain adequate and accurate source documents 
(medical records, electrocardiograms [ECGs], AE and concomitant medication reporting, and 
raw data collection forms) designed to record all observations and other pertinent data for each 
patient.  
Data entered in the eCRF that are transcribed from source documents must be consistent with the 
source documents or the discrepancies must be explained. The Investigator may need to request 
previous medical records or transfer records, depending on the st udy. Also, current medical 
records must be available.  
13.8 Study and Site Closure  
The Sponsor or designee reserves the right to close the investigational site or terminate the study 
at any time for any reason at their sole discretion. An investigational site is  considered closed 
when all required documents and study supplies have been collected and an investigational site 
closure visit has been performed. Portable Document Format versions of data entered in the 
eCRF will be distributed to the sites at time of st udy closure and not during an individual site 
close -out visit.  
The Investigator may initiate investigational site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.  
Reasons for the  early closure of an investigational site by the Sponsor or Investigator may 
include but are not limited to:  
Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or local 
health authorities, the Sponsor’s procedures, or GCP guidelines  
Inadequate recruitment of patients by the Investigator  
Discontinuation of further Tipifarnib development  
13.9 Publication Policy  
The full terms regarding publication of the results of this study are outlined in the applicable 
Clinical Study Agreement.  
14 Guidelines To Be Applied During Infectious Disease Outbreak 
– COVID -19 
Period:  
These guidelines  only apply during any  public health emergency related to COVID -19, declared 
by government authorities , in the countries where  the trial sites are located . 
 

Tipifarnib   
CTP KO-TIP-007          Page 93  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   The activities in this guideline include : 
- Safety reporting by Sites  
- Adherence to protocol specified activities  
- Informed Consent process  
- Provision of study drug to subjects  
- Site monitoring by CRAs  
- Documentation requirements  
. 
14.1 Ensuring Continuity of Safety Reporting  
Investigators may conduct tele -medicine calls via phone/video to identify or to follow -up on 
adverse events.   
In the event that patients cannot complete a site visit, they may be directed to utilize local 
labs/primary care providers to collect labs and conduct patient assessments (e.g., vitals, physical 
exams), and use local imaging facilities where necessary.  
If the patient cannot get to an alternative location, then the decision to continue dosing in 
absence of requi red safety labs is made by the investigator in consultation with the Kura Medical 
Monitor.  These decisions will be made on a case by case basis.  
For any reports of flu-like symptoms, fevers and/or respiratory problems; the investigator  should 
determine if  the patient has been /should be  tested for COVID -19.   
14.2 Maintaining Protocol Requirements, Including Schedule of Activities  
Exposure to or instances of a confirmed positive result for COVID -19 will not mandate early 
termination of patient from the study.  Continued participation in the study will be at the 
investigator ’s discretion.  
However, if investigators  have suspected / co nfirmed positive patients, then they should notify 
Kura Oncology. The investigator  and the Medical Monitor should make a case by case 
assessment of which procedures/samples are appropriate to continue.   
 
14.2.1  Clinic Visits  
• If patients cannot travel to the stud y site or the investigator  cannot accommodate a visit, but 
can still receive care via a local provider, efforts should be made to collect data from the 
local provider in accordance with local privacy/data protection requirements.  Data collected 
may includ e but is not limited to collection of weight and vital signs (heart rate, blood 
pressure, temperature) .  If possible, the investigator should prospectively request that data be 
collected according to good documentation practices (i.e., ALCOA+).  
• Where appli cable, patient visits may be conducted virtually via telephone or video 
conference.  Data collected during calls may include, but is not limited to adverse event 
assessment, concomitant medication assessment, ECOG assessments, survival follow -up, and 
IP co mpliance assessment.  Investigators should ensure:  

Tipifarnib   
CTP KO-TIP-007          Page 94  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   o Site staff or investigators are appropriately trained on how to conduct real -time 
video conferencing visits (i.e. training on use of telemedicine for remote clinical 
trial visits)  
o Necessary procedures and  safeguards are in place to maintain a trial participant’s 
privacy  
o Both the investigator and trial participant confirm their respective identities with 
one another before starting a real -time video conference visit  (e.g. have the trial 
participant confirm their date of birth or, if the visit is conducted via 
videoconference, present a form of government issued photographic 
identification)   Consult with the Sponsor or designee to confirm the specifics of 
any process implemented.  
o Details about the date and ti me of the real -time video conference visit, the 
location of the trial subject, the location of the investigator or staff conducting the 
visit should be  appropriately  documented.  
• Radiographic imaging may be collected locally and reviewed by the investigator  or 
applicable delegated staff member.   
14.2.2  Clinical Laboratory Testing  
• Clinical laboratory testing may be completed by a certified (e.g., CAP) local provider and 
reviewed by the investigator.  Laboratory results should be reviewed prior to either 
administration or additional shipping of IP.  
• If a local clinical laboratory wil l collect samples that require use of study specific laboratory 
kits ( , buccal swabs), laboratory kits may be shipped to the study subject to 
take with them to the local laboratory for use during testing.   
• If a local laboratory is utilized , the normal ranges for this lab need to be collected and the 
source of these values (i.e. coming from a local laboratory) needs to be clearly documented   
14.2.3  Disruptions for Shipping to Central Laboratories  
If the ability to ship samples to the Central Labor atory for analysis are impacted, then, if local 
facilities are available, it is permissible to store samples according to laboratory manual 
guidelines for analysis later when disruptions are resolved. Central laboratories should be 
consulted to resolve any  questions.   
 
14.3 Informed Consent Process  
When it is not possible to obtain informed consent in a face -to-face consent interview, it is 
permissible to obtain informed consent virtually.  Such virtual consent interviews need to ensure 
that an adequate exchange of information and documentation occur s.  In addition, there needs to 
be a method to ensure that the person who plans to enroll as a subject (or who is already enrolled 
as a subject in the case of a revised ICF) is actually the person who signs the ICF.  This virtual 
process can involve, for e xample, telephone or other video -conference mechanisms, along with 
the subject providing photographic or facsimile evidence of completing the ICF.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
Consult with the Sponsor or designee to confirm the specifics of any process implemented.  

Tipifarnib   
CTP KO-TIP-007          Page 95  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   14.4 Ensuring Continuity of Drug Supply to Subjects  
 
Investigational Product (IP) Shipping:  
• If site visit restrictions are anticipated but are not yet in effect, additional IP (beyond one 
cycle) may be dispensed during on -site patient visits  at the Investigator’s discretion .   
• If site visit restrictions are implemented between patient visits, IP may be shipped directly 
from sites to patients under the investigator’ s supervision via overnight courier along with 
instructions for dosing and documentation of dosing.  Delivery signature confirmation should 
be requested whenever possible.  IP should be shipped at ambient temperature using an 
insulated package/container.  Appropriate safeguards should be used to ensure appropriate 
shipping and receipt, including  documentation of receipt (signature of receiver ) and condition 
of package (e.g. ensur ing no tamper proof seal had been broken , etc.) 
• The IP may be shipped at ambient temp in credo with no temperature monitoring device . 
• Consult with Sponsor, or designee, as needed to assign IP .   
 
14.5 Managing Restrictions to Site Monitoring by CRAs  
Where there are physical access restrictions to clinical sites or country specific t ravel limitations, 
implementation of remote  or off -site monitoring visits (OMVs) may be conducted in lieu of on -
site visits whenever possible.  
OMVs should not place an extra burden on trial sites, and subjects must consent to any sharing 
of their personal  information outside the trial site.  
14.6 Documentation of COVID -19 Related Guidelines or Other Measures.  
It is important to document the reason for implementing any of these contingency measures. 
Such documentation should include details on how restrictions related to COVID -19 led to the 
use of these contingency measures during study conduct, the duration of those changes, which 
trial participants were impacted an d how those trial participants were impacted. When any non -
study site labs are needed, these should be clearly documented so that the Sponsor can align on 
usability of the data on a case -by-case basis.  When adopting or implementing these guidelines, 
inves tigators should make every effort to minimize any impacts on trial integrity.  If any 
additional changes are required that are not covered in these guidelines, investigators should act 
according to local guidelines and regulations, but above all to assure the safety of trial 
participants, maintaining compliance with good clinical practice (GCP), and minimizing  risks to 
trial integrity.  Any changes made should be appropriately documented as protocol deviations.  
 
In advance of any interim analyses/planned dat abase locks, the Sponsor will ensure that the 
impact from study visit changes a re assessed and will revise the SAP accordingly.  
15 LITERATURE  
Adjei AA, Mauer A, Bruzek L, Marks RS, Hillman S, Geyer S, Hanson LJ, Wright JJ, Erlichman 
C, Kaufmann SH, Vokes EE. Phase II study of the farnesyl transferase inhibitor R115777 in 
patients with advanced non -small -cell lung cancer. J Clin Oncol 2003 May 1;21(9):1760 -6 

Tipifarnib   
CTP KO-TIP-007          Page 96  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   Ahn MJ, D'Cruz A,  Vermorken JB,  Chen JP,  Chitapanarux I,  Dang HQ,  Guminski 
A, Kannarunimit D,  Lin TY , Ng WT,  Park KU,  Chan AT.  Clinical recommendations for 
defining  platinum  unsuitable head and neck cancer patient populations on chemoradiotherapy: A 
literature review.  Oral Oncol  2016 Feb;53:10 -6  
Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Pri ce-Troska T, Overton RM, Ahmann 
G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, 
Greipp PR, Dalton WS, Sebti SM. Farnesyltransferase inhibitor tipifarnib is well tolerated, 
induces stabilization of disease, and inhibits  farnesylation and oncogenic/tumor survival 
pathways in patients with advanced multiple myeloma. Blood. 2004 May 1;103(9):3271 -7 
Aung KL  and Siu LL. Genomically personalized therapy in head and neck cancer.  Cancers of the 
Head & Neck  2016;1 :2 
Baines AT, Xu D, Der CJ. Inhibition of RAS for cancer treatment: the search continues. Future 
Med Chem. 2011 Oct;3(14):1787 -808 
Barrington R,  Subler  M, Rands  E, et al.  A Farnesyltransferase Inhibitor Induces Tumor 
Regression in Transgenic Mice Har boring Multiple Oncogenic Mutations by Mediating 
Alterations in Both Cell Cycle Control and Apoptosis.  Mol Cell Biol . 1998 Jan; 18(1):85 –92 
Berndt N, Hamilton AD, and Sebti SM. Targeting  protein prenylation for cancer therapy. Nat 
Rev Cancer 2011;11:775 -91 
Braig F, Voigtlaender M, Schieferdecker A et al. Liquid biopsy monitoring uncovers acquired 
RAS -mediated resistance to cetuximab in a substantial proportion of patients with head and ne ck 
squamous cell carcinoma. Oncotarget 2016;7:42988 -42995  
Chaturvedi AK, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the 
United States. J Clin Oncol 2011; 29:4294 –4301  
Chen, X., et al. Transformation by Hras(G12V) is consistentl y associated with mutant allele copy 
gains and is reversed by farnesyl transferase inhibition. Oncogene 2014; 33:5442 -9 
Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin 
S, Rogatko A, Perez -Ruixo JJ, Thistle AM, Verhae ghe T, Wang H, Weiner LM, Wright JJ, 
Hudes GR, Meropol NJ. Phase II and pharmacodynamic study of the farnesyltransferase 
inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J 
Clin Oncol. 2003 Apr 1;21(7):1301 -6 
End D W, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet 
H, Skrzat S, Devine A, Wouters W, Bowden C. Characterization of the antitumor effects of the 
selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Ca ncer Res. 2001 
Jan 1;61(1):131 -7 
Eisenhauer EA , Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: 
Revised RECIST guideline (version 1.1). Eur J Cancer . 2009 Jan;45(2): 228 –47. 

Tipifarnib   
CTP KO-TIP-007          Page 97  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   Endhardt J, et al. Harvey ras (HRAS) mutations in head and neck cancer (HNC) and dependence 
on PI3K signaling and resistance to EGFR inhibition. J Clin Oncol 2014;32:5s, 2014 (suppl; 
abstr 6034)  
Ferris RL., Blumenschein G.,  Fayette J., Guigay J., Colevas AD., Licitra L., et al. Nivolumab 
for Recurrent Squamous -Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375:1856 -
1867  
Gajewski TF, Salama AK, Niedzwiecki D, Johnson J, Linette G, Bucher C, Blaskovich MA, 
Sebti SM, Haluska F; Cancer and Leukemia Group B. Phase II study of the farnesyltransferase 
inhibitor R115777 in advanced melanoma (CALGB  500104). J Transl Med 2012 Dec 10;10:246  
Hah JH, Zhao M, Pickering CR, Frederick MJ et al. HRAS mutations and resistance to the 
epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous 
cell carcinoma cells. Head Neck 2014;36:1547 -54 
Heymach JV, Johnson DH, Khuri FR, Safran H, Schlabach LL, Yunus F, DeVore RF 3rd, De 
Porre PM, Richards HM, Jia X, Zhang S, Johnson BE. Phase II study of the farnesyl transferase 
inhibitor R115777 in patients with sensitive relapse small -cell lung cancer. Ann Oncol 2004 
Aug;15(8):1187 -93 
Ho A, Chau N, Wong DJ, Cabanillas ME, Bauman J, Brose MS, Bible K, Boni V, Brana I, Ferte 
C, Even C, Burrows F, Kessler L, Mishra V, Magnuson K, Scholz C, Gualberto A. Preliminary 
results from a phase 2 proo f of concept trial of tipifarnib in tumors with HRAS mutations 
[abstract]. In: Proceedings of the AACR -NCI-EORTC International Conference: Molecular 
Targets and Cancer Therapeutics; 2017 Oct 26 -30; Philadelphia, PA. Philadelphia (PA): AACR; 
Mol Cancer Ther  2018;17(1 Suppl):Abstract nr LB -A10.  
Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, 
Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. 
Inhibition of the RAS/Raf/MEK/ERK and RET kinase path ways with the combination of the 
multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and 
differentiated thyroid malignancies. J Clin Endocrinol Metab 2011 Apr;96(4):997 -1005  
Johnston SR, Hickish T, Ellis P, Houston  S, Kelland L, Dowsett M, Salter J, Michiels B, Perez -
Ruixo JJ, Palmer P, Howes A. Phase II study of the efficacy and tolerability of two dosing 
regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 
2003 Jul 1;21( 13):2492 -9  
Kirschbaum MH, Synold T, Stein AS, Tuscano J, Zain JM, Popplewell L, Karanes C, O'Donnell 
MR, Pulone B, Rincon A, Wright J, Frankel P, Forman SJ, Newman EM. A phase 1 trial dose -
escalation study of tipifarnib on a week -on, week -off schedule in relapsed, refractory or high -risk 
myeloid leukemia. Leukemia. 2011 Oct;25(10):1543 -7  
Kohl, N.E., et al. Inhibition of farnesyltransferase induces regression of mammary and salivary 
carcinomas in ras transgenic mice. Nat Med 1995;1:792 -7 

Tipifarnib   
CTP KO-TIP-007          Page 98  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   Kurzrock R, Albita r M, Cortes JE, Estey EH, Faderl SH, Garcia -Manero G, Thomas DA, Giles 
FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM. Phase II study of R115777, a farnesyl 
transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004 Apr 1;22(7):1287 -92 
Lara PN Jr, Law LY, Wright JJ, Frankel P, Twardowski P, Lenz HJ, Lau DH, Kawaguchi T, 
Gumerlock PH, Doroshow JH, Gandara DR. Intermittent dosing of the farnesyl transferase 
inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I Californi a Cancer 
Consortium Trial. Anticancer Drugs. 2005 Mar;16(3):317 -21 
Leemans CR, et al.  The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9 -
22 
Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. Inhibition of the 
prenylation of K -Ras, but not H - or N-Ras, is highly resistant to CAAX peptidomimetics and 
requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor 
cell lines. Oncogene 1997 Sep;15(11):1283 -8 
Mahgoub, N., et al. In vit ro and in vivo effects of a farnesyltransferase inhibitor on Nf1 -deficient 
hematopoietic cells. Blood 1999; 94:2469 -76 
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and 
response criteria of the Eastern Cooperative Oncology  Group. Am J Clin Oncol 1982;5:649 -55 
Rampias T, Giagini A, Siolos S et al. RAS/PI3K crosstalk and cetuximab resistance in head and 
neck squamous cell carcinoma. Clin Cancer Res 2014 20:2933 -46 
Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Hu mblet Y, Kourteva G, 
Iveson T, Andre T, Dostalova J, Illes A, Belly R, Perez -Ruixo JJ, Park YC, Palmer PA. Phase III 
double -blind placebo -controlled study of farnesyl transferase inhibitor R115777 in patients with 
refractory advanced colorectal cancer. J C lin Oncol 2004 Oct 1;22(19):3950 -7 
Rosenberg JE, von der Maase H, Seigne JD, Mardiak J, Vaughn DJ, Moore M, Sahasrabudhe D, 
Palmer PA, Perez -Ruixo JJ, Small EJ. A phase II trial of R115777, an oral farnesyl transferase 
inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 2005 May 
15;103(10):2035 -41 
Seiwert TY, et al. Safety and clinical activity of  pembrolizumab  for treatment of recurrent or 
metastatic squamous cell carcinoma of the  head  and neck  (KEYNOTE -012): an open -label, 
multicentre, phase 1b trial. Lancet Oncol  2016 Jul;17(7):956 -65 
Takashima A, Faller DV. Targeting the RAS oncogene. Expert Opin Ther Targets 2013 
May;17(5):507 -31 
The Cancer Genome Atlas Network (TCGA). Comprehensive genomic characterization of head 
and neck squamous cell carcinomas. Nature 2015;517:576 –582 

Tipifarnib   
CTP KO-TIP-007          Page 99  
 
 
Amendment 3, 9 June 2020  
CONFIDENTIAL   Trempus CS, et al. A farnesyl transferase inhibitor suppresses TPA -mediated skin tumor 
development without altering hyperplasia in the ras transgenic Tg.AC mouse. Mol Carcinog 
2000; 27:24 -33 
Vermor ken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, 
Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, 
Schueler A, Amellal N, Hitt R.  Platinum -based chemotherapy plus cetuximab in head an d neck 
cancer.   N Engl J Med 2008 Sep 11;359(11):1116 -27 
Wang Z, Martin D, Molinolo AA et al. mTOR co -targeting in cetuximab resistance in head and 
neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst 2014 Aug 5;106(9)  
Whyte DB, et al. K - and N -Ras are geranylgeranylated in cells treated with farnesyl  protein 
transferase inhibitors. J Biol Chem 1997; 272:14459 -64 
Witzig T, Sokol L, Jacobsen E, et al. The CXCL12/CXCR4 Pathway As a Potential Target of 
Tipifarnib: Preliminary Results from an Open -Label, Phase II Study in Relapsed or Refractory 
Peripheral T-Cell Lymphoma.  Blood 2017 130:2788  
Yao, R., et al. Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor 
model: role of Ha -ras mutations and use of microarray analysis in identifying potential targets. 
Carcinogenesis 2006; 27:1420 -31 
Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, 
Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, 
Nussenblatt RB, Kremer AB, Cowan KH. Phase I and pharmacokinetic study of farn esyl protein 
transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000 Feb;18(4):927 -41 
  
